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ABBREVIATIONS AND ACRONYMS
DPm Mean transvalvular pressure gradient
2D Two-dimensional
3D Three-dimensional
ABC Age, biomarkers, clinical history
ACE Angiotensin-converting enzyme
ACS Acute coronary syndrome
ARB Angiotensin receptor blocker
AVA Aortic valve area
BAV Balloon aortic valvuloplasty
BNP B-type natriuretic peptide
BSA Body surface area
CABG Coronary artery bypass grafting
CAD Coronary artery disease
CI Contra-indication(s)
CMR Cardiovascular magnetic resonance
CPG Committee for Practice Guidelines cardiac
resynchronization therapy
CT Computed tomography
EACTS European Association for Cardio-Thoracic
Surgery
ECG Electrocardiogram
EDV End-diastolic velocity
EROA Effective regurgitant orifice area
ESC European Society of Cardiology
EuroSCORE European System for Cardiac Operative Risk
Evaluation
INR International normalized ratio
IV Intravenous
LA Left atrium/left atrial
LMWH Low-molecular-weight heparin
LV Left ventricle/left ventricular
LVEDD Left ventricular end-diastolic diameter
LVEF Left ventricular ejection fraction
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LVOT Left ventricular outflow tract
MSCT Multislice computed tomography
NOAC Non-vitamin K antagonist oral anticoagulant
NYHA New York Heart Association
PCI Percutaneous coronary intervention
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RV Right ventricle/right ventricular
SAVR Surgical aortic valve replacement
SPAP Systolic pulmonary arterial pressure
STS Society of Thoracic Surgeons
SVi Stroke volume index
TAVI Transcatheter aortic valve implantation
TOE Transoesophageal echocardiography
TTE Transthoracic echocardiography
TVI Time–velocity interval
UFH Unfractionated heparin
VHD Valvular heart disease
VKA Vitamin K antagonist
Vmax Peak transvalvular velocity
1. PREAMBLE
Guidelines summarize and evaluate available evidence with the
aim of assisting health professionals in selecting the best
management strategies for an individual patient with a given
condition. Guidelines and their recommendations should facili-
tate decision making of health professionals in their daily prac-
tice. However, the final decisions concerning an individual
patient must be made by the responsible health professional(s) in
consultation with the patient and caregiver as appropriate.
A great number of guidelines have been issued in recent years
by the European Society of Cardiology (ESC) and by the European
Association for Cardio-Thoracic Surgery (EACTS) as well as by
other societies and organisations. Because of the impact on clinical
practice, quality criteria for the development of guidelines have
been established in order to make all decisions transparent to the
user. The recommendations for formulating and issuing ESC
Guidelines can be found on the ESC website (https://www.escar
dio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-develop
ment/Writing-ESC-Guidelines). ESC Guidelines represent the offi-
cial position of the ESC on a given topic and are regularly updated.
Members of this Task Force were selected by the ESC and
EACTS to represent professionals involved with the medical care
of patients with this pathology. Selected experts in the field
undertook a comprehensive review of the published evidence for
management of a given condition according to ESC Committee
for Practice Guidelines (CPG) policy and approved by the EACTS.
A critical evaluation of diagnostic and therapeutic procedures
was performed, including assessment of the risk–benefit ratio.
The level of evidence and the strength of the recommendation of
particular management options were weighed and graded ac-
cording to predefined scales, as outlined in Tables 1 and 2.
The experts of the writing and reviewing panels provided dec-
laration of interest forms for all relationships that might be per-
ceived as real or potential sources of conflicts of interest. These
forms were compiled into one file and can be found on the ESC
website (http://www.escardio.org/guidelines). Any changes in
declarations of interest that arise during the writing period were
notified to the ESC and EACTS and updated. The Task Force
received its entire financial support from the ESC and EACTS
without any involvement from the healthcare industry.
The ESC CPG supervises and coordinates the preparation of
new Guidelines. The Committee is also responsible for the en-
dorsement process of these Guidelines. The ESC Guidelines
undergo extensive review by the CPG and external experts, and
in this case by EACTS-appointed experts. After appropriate revi-
sions the Guidelines are approved by all the experts involved in
the Task Force. The finalized document is approved by the CPG
and EACTS for publication in the European Heart Journal and in
the European Journal of Cardio-Thoracic Surgery. The Guidelines
were developed after careful consideration of the scientific and
medical knowledge and the evidence available at the time of
their dating.
The task of developing ESC/EACTS Guidelines also includes the
creation of educational tools and implementation programmes
for the recommendations including condensed pocket guideline
versions, summary slides, booklets with essential messages, sum-
mary cards for non-specialists and an electronic version for digi-
tal applications (smartphones, etc.). These versions are abridged
and thus, if needed, one should always refer to the full text ver-
sion, which is freely available via the ESC website and hosted on
the EHJ website. The National Societies of the ESC are encour-
aged to endorse, translate and implement all ESC Guidelines.
Implementation programmes are needed because it has been
shown that the outcome of disease may be favourably influenced
by the thorough application of clinical recommendations.
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Surveys and registries are needed to verify that real-life daily
practice is in keeping with what is recommended in the guide-
lines, thus completing the loop between clinical research, writing
of guidelines, disseminating them and implementing them into
clinical practice.
Health professionals are encouraged to take the ESC/EACTS
Guidelines fully into account when exercising their clinical judg-
ment, as well as in the determination and the implementation of
preventive, diagnostic or therapeutic medical strategies.
However, the ESC/EACTS Guidelines do not override in any way
whatsoever the individual responsibility of health professionals to
make appropriate and accurate decisions in consideration of
each patient’s health condition and in consultation with that pa-
tient or the patient’s caregiver where appropriate and/or neces-
sary. It is also the health professional’s responsibility to verify the
rules and regulations applicable to drugs and devices at the time
of prescription.
2. INTRODUCTION
2.1. Why do we need new guidelines on valvular
heart disease?
Since the previous version of the guidelines on the manage-
ment of VHD was published in 2012, new evidence has
accumulated, particularly on percutaneous interventional
techniques and on risk stratification with regard to timing of
intervention in VHD. This made a revision of the recommen-
dations necessary.
2.2. Content of these guidelines
Decision making in VHD involves accurate diagnosis, timing of
intervention, risk assessment and, based on these, selection of
the most suitable type of intervention. These guidelines focus on
acquired VHD, are oriented towards management and do not
deal with endocarditis or congenital valve disease, including pul-
monary valve disease, as separate guidelines have been published
by the ESC on these topics.
2.3. New format of the guidelines
The new guidelines have been adapted to facilitate their use in
clinical practice and to meet readers’ demands by focusing on
condensed, clearly represented recommendations. At the end of
each section, Key points summarize the essentials. Gaps in evidence
are listed to propose topics for future research. The guideline
document is harmonized with the simultaneously published chap-
ter on VHD of the ESC Textbook of Cardiology, which is freely
available by Internet access (https://academic.oup.com/eurheartj/
article-lookup/doi/10.1093/eurheartj/ezx324#supplementary-data).
Table 2: Levels of evidence
Level of 
evidence A 
Data derived from multiple randomized 
clinical trials or meta-analyses. 
Level of 
evidence B 
Data derived from a single randomized 
clinical trial or large non-randomized 
studies. 
Level of 
evidence C 
Consensus of opinion of the experts and/
or small studies, retrospective studies, 
registries.
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Table 1: Classes of recommendations
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The guidelines and the textbook are complementary. Background
information and detailed discussion of the data that have provided
the basis for the recommendations can be found in the relevant
book chapter.
2.4 How to use these guidelines
The Committee emphasizes that many factors ultimately deter-
mine the most appropriate treatment in individual patients
within a given community. These factors include the availability
of diagnostic equipment, the expertise of cardiologists and sur-
geons, especially in the field of valve repair and percutaneous
intervention and, notably, the wishes of well-informed patients.
Furthermore, owing to the lack of evidence-based data in the
field of VHD, most recommendations are largely the result of ex-
pert consensus opinion. Therefore, deviations from these guide-
lines may be appropriate in certain clinical circumstances.
3. GENERAL COMMENTS
The aims of the evaluation of patients with VHD are to diagnose,
quantify and assess the mechanism of VHD as well as its conse-
quences. Decision making for intervention should be made by a
‘Heart Team’ with a particular expertise in VHD, comprising car-
diologists, cardiac surgeons, imaging specialists, anaesthetists
and, if needed, general practitioners, geriatricians and heart fail-
ure, electrophysiology or intensive care specialists. The ‘Heart
Team’ approach is particularly advisable in the management of
high-risk patients and is also important for other subsets, such as
asymptomatic patients where the evaluation of valve reparability
is a key component in decision making. The essential questions
in the evaluation of a patient for valvular intervention are sum-
marized in Table 3.
3.1 Patient evaluation
Precise evaluation of the patient’s history and symptomatic status
as well as proper physical examination, in particular auscultation
and search for heart failure signs, are crucial for the diagnosis
and management of VHD. In addition, assessment of the extrac-
ardiac condition—comorbidities and general condition—require
particular attention.
3.1.1 Echocardiography. Following adequate clinical evalu-
ation, echocardiography is the key technique used to confirm the
diagnosis of VHD as well as to assess its severity and prognosis. It
should be performed and interpreted by properly trained per-
sonnel [1].
Echocardiographic criteria for the definition of severe valve
stenosis and regurgitation are addressed in specific documents
[2–4]. Recommendations for stenotic lesions are indicated in the
corresponding sections and quantification of regurgitant lesions
is summarized in Table 4. An integrated approach including vari-
ous criteria is strongly recommended instead of referring to sin-
gle measurements. Echocardiography is also key to assess valve
morphology and function as well as to evaluate the feasibility
and indications of a specific intervention.
Indices of left ventricular (LV) enlargement and function are
strong prognostic factors. Pulmonary artery pressure should be
estimated as well as right ventricular (RV) function [5].
Transoesophageal echocardiography (TOE) should be considered
when transthoracic echocardiography (TTE) is of suboptimal
quality or when thrombosis, prosthetic valve dysfunction or
endocarditis is suspected. Intraprocedural TOE is used to guide
percutaneous mitral and aortic valve interventions and to moni-
tor the results of all surgical valve operations and percutaneous
valve implantation or repair.
3.1.2 Other non-invasive investigations.
3.1.2.1 Stress testing. The primary purpose of exercise testing is to
unmask the objective occurrence of symptoms in patients who
claim to be asymptomatic or have non-specific symptoms, and is
especially useful for risk stratification in aortic stenosis [8].
Exercise testing will also determine the level of recommended
physical activity, including participation in sports.
Exercise echocardiography may identify the cardiac origin of
dyspnoea. The prognostic impact has been shown mainly for
aortic stenosis and mitral regurgitation [9].
The search for flow reserve (also called ‘contractile reserve’)
using low-dose dobutamine stress echocardiography is useful for
assessing aortic stenosis severity and for operative risk stratifica-
tion in low-gradient aortic stenosis with impaired LV function as
well as to assess the potential of reverse remodelling in patients
with heart failure and functional mitral regurgitation after a mitral
valve procedure [10, 11].
3.1.2.2 Cardiac magnetic resonance. In patients with inadequate
echocardiographic quality or discrepant results, cardiac magnetic
resonance (CMR) should be used to assess the severity of valvular
Table 3: Essential questions in the evaluation of patients for
valvular intervention
VHD: valvular heart disease.
aLife expectancy should be estimated according to age, sex, comorbid-
ities, and country-specific life expectancy.
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lesions, particularly regurgitant lesions, and to assess ventricular
volumes, systolic function, abnormalities of the ascending aorta
and myocardial fibrosis. CMR is the reference method for the
evaluation of RV volumes and function and is therefore particu-
larly useful to evaluate the consequences of tricuspid regurgita-
tion [12].
3.1.2.3 Computed tomography. Multislice computed tomography
(MSCT) may contribute to evaluation of the severity of valve dis-
ease, particularly in aortic stenosis [13, 14] and of the thoracic
aorta. MSCT plays an important role in the workup of patients
with VHD considered for transcatheter intervention, in particular
transcatheter aortic valve implantation (TAVI), and provides valu-
able information for pre-procedural planning. Owing to its high
negative predictive value, MSCT may be useful to rule out coron-
ary artery disease (CAD) in patients who are at low risk of
atherosclerosis.
3.1.2.4 Cinefluoroscopy. Cinefluoroscopy is particularly useful for
assessing the kinetics of the occluders of a mechanical prosthesis.
3.1.2.5 Biomarkers. B-type natriuretic peptide (BNP) serum levels
are related to New York Heart Association (NYHA) functional
class and prognosis, particularly in aortic stenosis and mitral re-
gurgitation [15]. Natriuretic peptides may be of value for risk
stratification and timing of intervention, particularly in asymp-
tomatic patients.
3.1.3 Invasive investigations.
3.1.3.1 Coronary angiography. Coronary angiography is indicated
for the assessment of CAD when surgery or an intervention is
planned, to determine if concomitant coronary revascularization
is indicated (see following table of recommendations) [16].
Alternatively, coronary computed tomography (CT) can be used
to rule out CAD in patients at low risk for the condition.
Table 4: Echocardiographic criteria for the definition of severe valve regurgitation: an integrative approach (adapted from
Lancellotti et al. [2, 6, 7])
CW: continuous wave; EDV: end-diastolic velocity; EROA: effective regurgitant orifice area; LA: left atrium/atrial; LV: left ventricle/ventricular; PISA: proximal
isovelocity surface area; RA: right atrium/right atrial; RV: right ventricle; TR: tricuspid regurgitation; TVI: time–velocity integral.
aAt a Nyquist limit of 50–60 cm/s.
bFor average between apical four- and two-chamber views.
cUnless other reasons for systolic blunting (atrial fibrillation, elevated atrial pressure).
dIn the absence of other causes of elevated LA pressure and of mitral stenosis.
eIn the absence of other causes of elevated RA pressure.
fPressure half-time is shortened with increasing LV diastolic pressure, vasodilator therapy, and in patients with a dilated compliant aorta, or lengthened in
chronic aortic regurgitation.
gBaseline Nyquist limit shift of 28 cm/s.
hDifferent thresholds are used in secondary mitral regurgitation where an EROA >20 mm2 and regurgitant volume >30 ml identify a subset of patients at
increased risk of cardiac events.
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3.1.3.2 Cardiac catheterization. The measurement of pressures and
cardiac output or the assessment of ventricular performance and
valvular regurgitation by ventricular angiography or aortography
is restricted to situations where non-invasive evaluation is incon-
clusive or discordant with clinical findings. When elevated
pulmonary pressure is the only criterion to support the indication
for surgery, confirmation of echo data by invasive measurement
is recommended.
3.1.4 Assessment of comorbidity. The choice of specific
examinations to assess comorbidity is directed by the clinical
evaluation.
3.2 Risk stratification
Risk stratification applies to any sort of intervention and is
required for weighing the risk of intervention against the ex-
pected natural history of VHD as a basis for decision making.
Most experience relates to surgery and TAVI. The EuroSCORE I
(http://www.euroscore.org/calc.html) overestimates operative
mortality and its calibration of risk is poor. Consequently, it
should no longer be used to guide decision making. The
EuroSCORE II and the Society of Thoracic Surgeons (STS) score
(http://riskcalc.sts.org/stswebriskcalc/#/) more accurately discrim-
inate high- and low-risk surgical patients and show better cali-
bration to predict postoperative outcome after valvular surgery
[17, 18]. Scores have major limitations for practical use by insuffi-
ciently considering disease severity and not including major risk
factors such as frailty, porcelain aorta, chest radiation etc. While
EuroSCORE I markedly overestimates 30-day mortality and
should therefore be replaced by the better performing
EuroSCORE II in this regard, it is nevertheless provided in this
document for comparison, as it has been used in many TAVI
studies/registries and may still be useful to identify the subgroups
of patients for decision between intervention modalities and to
predict 1-year mortality. Both scores have shown variable results
in predicting the outcomes of intervention in TAVI but are useful
for identifying low-risk patients for surgery. New scores have
been developed to estimate the risk of 30-day mortality in pa-
tients undergoing TAVI, with better accuracy and discrimination,
albeit with numerous limitations [19, 20].
Experience with risk stratification is being accumulated for
other interventional procedures, such as mitral edge-to-edge re-
pair. It remains essential not to rely on a single risk score figure
when assessing patients or to determine unconditionally the indi-
cation and type of intervention. Patient’s life expectancy, ex-
pected quality of life and patient preference should be
considered, as well as local resources. The futility of interventions
in patients unlikely to benefit from the treatment has to be taken
into consideration, particularly for TAVI and mitral edge-to-edge
repair [21]. The role of the Heart Team is essential to take all of
these data into account and adopt a final decision on the best
treatment strategy. Finally, the patient and family should be thor-
oughly informed and assisted in their decision on the best treat-
ment option [22].
3.3 Special considerations in elderly patients
Poor mobility, as assessed by the 6-minute walk test, and oxygen
dependency are the main factors associated with increased mor-
tality after TAVI and other VHD treatments [23, 24]. The combin-
ation of severe lung disease, postoperative pain from sternotomy
or thoracotomy and prolonged time under anaesthesia in pa-
tients undergoing traditional surgical aortic valve replacement
(SAVR) may contribute to pulmonary complications. There is a
Management of CAD in patients with VHD (adapted
fromWindecker et al. [16])
Recommendations Classa Levelb
Diagnosis of CAD
Coronary angiographyc is recommended
before valve surgery in patients with severe
VHD and any of the following:
• history of cardiovascular disease
• suspected myocardial ischaemiad
• LV systolic dysfunction
• in men >40 years of age and postmeno-
pausal women
• one or more cardiovascular risk factors.
I C
Coronary angiography is recommended in
the evaluation of moderate to severe sec-
ondary mitral regurgitation.
I C
CT angiography should be considered as
an alternative to coronary angiography
before valve surgery in patients with severe
VHD and low probability of CAD or in
whom conventional coronary angiography
is technically not feasible or associated
with a high risk.
IIa C
Indications for myocardial revascularization
CABG is recommended in patients with a
primary indication for aortic/mitral valve
surgery and coronary artery diameter
stenosis >_70%.e
I C
CABG should be considered in patients
with a primary indication for aortic/mitral
valve surgery and coronary artery diameter
stenosis >_50–70%.
IIa C
PCI should be considered in patients with
a primary indication to undergo TAVI and
coronary artery diameter stenosis >70% in
proximal segments.
IIa C
PCI should be considered in patients with
a primary indication to undergo transcath-
eter mitral valve interventions and coro-
nary artery diameter stenosis >70% in
proximal segments.
IIa C
CABG: coronary artery bypass grafting; CAD: coronary artery disease;
CT: computed tomography; LV: left ventricular; MSCT: multislice
computed tomography; PCI: percutaneous coronary intervention;
TAVI: transcatheter aortic valve implantation; VHD: valvular heart
disease.
aClass of recommendation.
bLevel of evidence.
cMSCT may be used to exclude CAD in patients who are at low risk of
atherosclerosis.
dChest pain, abnormal non-invasive testing.
e>_50% can be considered for left main stenosis.
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gradual relationship between the impairment of renal function
and increased mortality after valvular surgery, TAVI and trans-
catheter mitral edge-to-edge repair [25], especially when glom-
erular filtration rate is < 30 ml/min. Coronary, cerebrovascular
and peripheral artery disease have a negative impact on early
and late survival after surgery and TAVI [22].
Besides specific organ comorbidities, there is growing interest
in the assessment of frailty, an overall marker of impairment of
functional, cognitive and nutritional status. Frailty is associated
with increased morbidity and mortality after surgery and TAVI
[26]. The assessment of frailty should not rely on a subjective ap-
proach, such as the ‘eyeball test’, but rather on a combination of
different objective estimates. Several tools are available for as-
sessing frailty [23, 26, 27].
3.4 Endocarditis prophylaxis
Antibiotic prophylaxis should be considered for high-risk proced-
ures in patients with prosthetic valves, including transcatheter
valves, or with repairs using prosthetic material and those with
previous episodes of infective endocarditis [28]. Recommendations
regarding dental and cutaneous hygiene and strict aseptic meas-
ures during any invasive procedures are advised in this population.
Antibiotic prophylaxis should be considered in dental procedures
involving manipulation of the gingival or periapical region of the
teeth or manipulation of the oral mucosa [28].
3.5 Prophylaxis for rheumatic fever
Prevention of rheumatic heart disease should preferably be ori-
ented towards preventing the first attack of acute rheumatic
fever. Antibiotic treatment of group A Streptococcus sore throat is
key in primary prevention. In patients with rheumatic heart dis-
ease, secondary long-term prophylaxis against rheumatic fever is
recommended. Lifelong prophylaxis should be considered in
high-risk patients according to the severity of VHD and exposure
to group A Streptococcus [29–31].
3.6 Concept of the Heart Team and heart valve
centres
The main purpose of heart valve centres as centres of excellence
in the treatment of VHD is to deliver better quality of care. This is
achieved through greater volumes associated with specialization of
training, continuing education and clinical interest. Specialization
will also result in timely referral of patients before irreversible ad-
verse effects occur and evaluation of complex VHD conditions.
Techniques with a steep learning curve may be performed with
better results in hospitals with high volumes and more experience
[32]. These main aspects are presented in Table 5.
A heart valve centre should have structured training pro-
grammes [32]. Surgeons and cardiologists performing any valve
intervention should undergo focused training as part of their
basic local board certification training. Learning new techniques
should take place through mentoring to minimize the effects of
the ‘learning curve’.
The relationship between case volume and outcomes for sur-
gery and transcatheter interventions is complex but should not
be denied [33–35]. However, the precise numbers of procedures
per individual operator or hospital required to provide high-
quality care remain controversial and more scientific data are
required before solid recommendations can be provided.
Nevertheless, standards for provision of cardiac surgery that con-
stitute the minimal core requirements have been released [36].
Experience in the full spectrum of surgical procedures—including
valve replacement; aortic root surgery; mitral, tricuspid and aortic
valve repair; repair of complicated valve endocarditis such as
root abscess; treatment of atrial fibrillation as well as surgical
myocardial revascularization—must be available. The spectrum of
interventional procedures in addition to TAVI should include mi-
tral valvuloplasty, mitral valve repair (edge-to-edge), closure of
atrial septal defects, closure of paravalvular leaks and left atrial
(LA) appendage closure as well as percutaneous coronary inter-
vention (PCI). Expertise in interventional and surgical manage-
ment of vascular diseases and complications must be available.
Comprehensive recording of performance and patient outcome
data at the level of the given heart valve centre is essential, as
well as participation in national or ESC/EACTS registries.
3.7 Management of associated conditions
3.7.1 Coronary artery disease. The use of stress tests to detect
CAD associated with severe valvular disease is discouraged be-
cause of their low diagnostic value and potential risks. A sum-
mary of the management of associated CAD is given in section
3.1.3.1 (see table of recommendations on the management
of CAD in patients with VHD) and is detailed in specific guide-
lines [16].
Table 5: Recommended requirements of a heart valve
centre (modified from Chambers et al. [32])
3D: three-dimensional; CT: computed tomography; MRI: magnetic
resonance imaging; TOE: transoesophageal echocardiography.
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3.7.2 Atrial fibrillation. Non-vitamin K antagonist oral anti-
coagulants (NOACs) are approved only for non-valvular atrial fib-
rillation, but there is no uniform definition of this term [37].
Recent subgroup analyses of randomized trials on atrial fibrilla-
tion support the use of rivaroxaban, apixaban, dabigatran and
edoxaban in patients with aortic stenosis, aortic regurgitation or
mitral regurgitation presenting with atrial fibrillation [38–41]. The
use of NOACs is discouraged in patients who have atrial fibrilla-
tion associated with moderate to severe mitral stenosis, given the
lack of data and the particularly high thromboembolic risk.
Despite the absence of data, NOACs may be used in patients
who have atrial fibrillation associated with an aortic bioprosthesis
>3 months after implantation but are strictly contraindicated in
patients with any mechanical prostheses [42, 43].
Surgical ablation of atrial fibrillation combined with mitral
valve surgery is effective in reducing the incidence of atrial fibril-
lation, but at the expense of more frequent pacemaker implant-
ation, and has no impact on short-term survival [44]. Surgical
ablation should be considered in patients with symptomatic atrial
fibrillation and may be considered in patients with asymptomatic
atrial fibrillation if feasible with minimal risk. The decision should
factor in other important variables, such as age, the duration of
atrial fibrillation and LA size. Surgical excision or external clipping
of the LA appendage may be considered combined with valvular
surgery, although there is no evidence that it decreases thrombo-
embolic risk. For patients with atrial fibrillation and risk factors
for stroke, long-term oral anticoagulation is currently recom-
mended, although surgical ablation of atrial fibrillation and/or
surgical LA appendage excision or exclusion may have been per-
formed [37]. Recommendations for the management of atrial fib-
rillation in VHD are summarized in the following table.
Key points
• Precise evaluation of the patient’s history and symptomatic
status as well as proper physical examination are crucial for
the diagnosis and management of VHD.
• Echocardiography is the key technique to diagnose VHD and
assess its severity and prognosis. Other non-invasive investiga-
tions such as stress testing, CMR, CT, fluoroscopy and bio-
markers are complementary, and invasive investigation
beyond preoperative coronary angiography is restricted to
situations where non-invasive evaluation is inconclusive.
• Risk stratification is essential for decision making to weigh the
risk of intervention against the expected natural history of VHD.
• Decision making in elderly patients requires special consider-
ations, including life expectancy and expected quality of life,
with regards to comorbidities and general condition (frailty).
• Heart valve centres with highly specialized multidisciplinary
teams, comprehensive equipment and sufficient volumes of
procedures are required to deliver high-quality care and pro-
vide adequate training.
• NOACs may be used in patients with atrial fibrillation and
aortic stenosis, aortic regurgitation, mitral regurgitation or
aortic bioprostheses >3 months after implantation but are
contraindicated in mitral stenosis and mechanical valves.
Gaps in evidence
• Better tools for risk stratification need to be developed, par-
ticularly for the decision between surgery and catheter inter-
vention and for the avoidance of futile interventions.
Management of atrial fibrillation in patients with VHD
Recommendations Classa Levelb
Anticoagulation
NOACs should be considered as an alternative to VKAs in patients with aortic stenosis, aortic regurgitation and mitral
regurgitation presenting with atrial fibrillation [38–41].
IIa B
NOACs should be considered as an alternative to VKAs after the third month of implantation in patients who have
atrial fibrillation associated with a surgical or transcatheter aortic valve bioprosthesis.
IIa C
The use of NOACs is not recommended in patients with atrial fibrillation and moderate to severe mitral stenosis. III C
NOACS are contraindicated in patients with a mechanical valve [45]. III B
Surgical interventions
Surgical ablation of atrial fibrillation should be considered in patients with symptomatic atrial fibrillation who undergo
valve surgery [37].
IIa A
Surgical ablation of atrial fibrillation may be considered in patients with asymptomatic atrial fibrillation who undergo
valve surgery, if feasible, with minimal risk.
IIb C
Surgical excision or external clipping of the LA appendage may be considered in patients undergoing valve surgery
[46].
IIb B
LA: left atrial; NOAC: non-vitamin K antagonist oral anticoagulant; VHD: valvular heart disease; VKA: vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
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• Minimum volumes of procedures per operator and per hos-
pital that are required to achieve optimal treatment results
need to be defined.
• The safety and efficacy of NOACs in patients with surgical or
transcatheter bioprostheses in the first 3 months after im-
plantation should be studied.
4. AORTIC REGURGITATION
Aortic regurgitation can be caused by primary disease of the aor-
tic valve cusps and/or abnormalities of the aortic root and as-
cending aortic geometry. Degenerative tricuspid and bicuspid
aortic regurgitation are the most common aetiologies in Western
countries, accounting for approximately two-thirds of the under-
lying aetiology of aortic regurgitation in the Euro Heart Survey
on VHD [47]. Other causes include infective and rheumatic endo-
carditis. Acute severe aortic regurgitation is mostly caused by in-
fective endocarditis and less frequently by aortic dissection.
4.1 Evaluation
4.1.1 Echocardiography. Echocardiography (TTE/TOE) is the
key examination to describe valve anatomy, quantify aortic re-
gurgitation, evaluate its mechanisms, define the morphology of
the aorta and determine the feasibility of valve-sparing aortic
surgery or valve repair [48, 49].
Essential aspects of this evaluation include:
• Assessment of valve morphology: tricuspid, bicuspid, unicus-
pid or quadricuspid valve.
• Determination of the direction of the aortic regurgitation jet
in the long-axis view (central or eccentric) and its origin in the
short-axis view (central or commissural).
• Identification of the mechanism, following the same principle as
for mitral regurgitation: normal cusps but insufficient coaptation
due to dilatation of the aortic root with central jet (type 1), cusp
prolapse with eccentric jet (type 2) or retraction with poor cusp
tissue quality and large central or eccentric jet (type 3) [48].
• Quantification of aortic regurgitation should follow an inte-
grated approach considering all qualitative, semi-quantitative
and quantitative parameters [2, 6] (Table 4).
• Measurement of LV function and dimensions. Indexing LV
diameters for body surface area (BSA) is recommended in pa-
tients with small body size (BSA <1.68 m2) [50]. New param-
eters obtained by three-dimensional (3D) echocardiography,
tissue Doppler and strain rate imaging may be useful, particu-
larly in patients with borderline left ventricular ejection fraction
(LVEF), where they may help in the decision for surgery [51].
• Measurement of the aortic root and ascending aorta in the 2-
dimensional (2D) mode at four levels: annulus, sinuses of
Valsalva, sinotubular junction and tubular ascending aorta [52].
Measurements are taken in the parasternal long-axis view from
leading edge to leading edge at end diastole, except for the
aortic annulus, which is measured in mid systole. As it will have
surgical consequences, it is important to differentiate three
phenotypes of the ascending aorta: aortic root aneurysms
(sinuses of Valsalva >45 mm), tubular ascending aneurysm
(sinuses of Valsalva <40–45 mm) and isolated aortic regurgita-
tion (all diameters <40 mm). The calculation of indexed values
has been recommended to account for body size [53].
• Definition of the anatomy of the aortic valve cusps and as-
sessment of valve reparability should be provided by pre-
operative TOE if aortic valve repair or a valve-sparing surgery
of the aortic root is considered.
• Intraoperative evaluation of the surgical result by TOE is man-
datory in patients in whom the aortic valve is preserved or re-
paired in the procedure.
4.1.2 Computed tomography and cardiac magnetic reso-
nance. CMR should be used to quantify the regurgitant fraction
when echocardiographic measurements are equivocal. In patients
with aortic dilatation, gated MSCT is recommended to assess the
maximum diameter. CMR can be used for follow-up, but indica-
tion for surgery should preferably be based on CT measurements.
Different methods of aortic measurements have been reported
and this may result in diameter discrepancies of 2–3 mm that
could influence therapeutic management. To improve reproduci-
bility, it is recommended to measure diameters using the inner-
inner edge technique at end diastole on the strictly transverse
plane by double oblique reconstruction perpendicular to the axis
of blood flow of the corresponding segment. Diameters at the an-
nulus, sinus of Valsalva, sinotubular junction, tubular ascending
aorta and aortic arch level should be reported. Maximum root
diameter should be taken from sinus to sinus rather than sinus to
commissure diameter, as it correlates more closely to long-axis
leading edge to leading edge echo maximum diameters [54, 55].
4.2 Indications for intervention
Acute aortic regurgitation may require urgent surgery. It is primar-
ily caused by infective endocarditis and aortic dissections. Specific
guidelines deal with these entities [28, 56]. The indications for
intervention in chronic aortic regurgitation are summarized on the
next page (recommendations on indications for surgery in severe
aortic regurgitation and aortic root disease) and in Figure 1 and
may be related to symptoms, status of the LV or dilatation of the
aorta.
In symptomatic patients, surgery is recommended irrespective
of the LVEF value, except for extreme cases, as long as aortic re-
gurgitation is severe and the operative risk is not prohibitive [57].
In asymptomatic patients with severe aortic regurgitation, im-
pairment of LV function (ejection fraction <_50%) and LV enlarge-
ment with an LV end-diastolic diameter (LVEDD) >70 mm or left
ventricular end-systolic diameter (LVESD) >50 mm are associated
with worse outcome and surgery should therefore be pursued
when these cut-offs are reached [58]. In patients with small body
size, LVESD should be related to BSA and a cut-off of 25 mm/m2
BSA appears to be more appropriate [50]. In patients not reach-
ing the thresholds for surgery, close follow-up is needed and ex-
ercise testing should be performed to identify borderline
symptomatic patients. In truly asymptomatic patients, regular as-
sessment of LV function and physical condition are crucial to
identify the optimal time for surgery. A rapid progression of ven-
tricular dimensions or decline in ventricular function on serial
testing is a reason to consider surgery.
In patients with a dilated aorta, the rationale for surgery has
been best defined in patients with Marfan syndrome and root
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dilation [59]. Root aneurysms need to have root replacement,
with or without preservation of the native aortic valve, but defin-
itely with coronary reimplantation. In contrast, tubular ascending
aortic aneurysms require only a supracommissural tube graft re-
placement without coronary reimplantation. In patients with aortic
diameters borderline for aortic surgery, the family history, age and
anticipated risk of the procedure should be taken into consider-
ation. In individuals with a bicuspid aortic valve and no significant
valve regurgitation, prophylactic surgery should be considered
with aortic diameters >_55 mm or >_ 50 mm when additional risk fac-
tors or coarctation are present (see table of recommendations on
indications for surgery in severe aortic regurgitation and aortic
root disease). Surgery is indicated in all patients with Marfan syn-
drome and a maximal aortic diameter >_50 mm. In patients with
Marfan syndrome and additional risk factors and in patients with a
TGFBR1 or TGFBR2 mutation (including Loeys–Dietz syndrome),
Figure 1: Management of aortic regurgitation. AR: aortic regurgitation; BSA:
body surface area; LVEDD: left ventricle end-diastolic diameter; LVEF: left ven-
tricular ejection fraction; LVESD: left ventricle end-systolic diameter.
aSee table of recommendations on indications for surgery in severe aortic
regurgitation and aortic root disease for definition.
bSurgery should also be considered if significant changes in LV or aortic size
occur during follow-up (see table of recommendations on indications for
surgery in severe aortic regurgitation and aortic root disease in section 4.2).
Indications for surgery in (A) severe aortic regurgitation
and (B) aortic root disease (irrespective of the severity
of aortic regurgitation)
Indications for surgery Classa Levelb
A. Severe aortic regurgitation
Surgery is indicated in symptomatic patients [57, 58, 66, 67]. I B
Surgery is indicated in asymptomatic patients with resting
LVEF <_50% [57, 58].
I B
Surgery is indicated in patients undergoing CABG or sur-
gery of the ascending aorta or of another valve.
I C
Heart Team discussion is recommended in selected
patientsc in whom aortic valve repair may be a feasible
alternative to valve replacement.
I C
Surgery should be considered in asymptomatic patients
with resting ejection fraction >50% with severe LV dilata-
tion: LVEDD >70 mm or LVESD >50 mm (or LVESD
>25 mm/m2 BSA in patients with small body size) [58, 66].
IIa B
B. Aortic root or tubular ascending aortic aneurysmd (irrespective of the
severity of aortic regurgitation)
Aortic valve repair, using the reimplantation or remodel-
ling with aortic annuloplasty technique, is recommended
in young patients with aortic root dilation and tricuspid
aortic valves, when performed by experienced surgeons.
I C
Surgery is indicated in patients with Marfan syndrome
who have aortic root disease with a maximal ascending
aortic diameter >_50 mm.
I C
Surgery should be considered in patients who have aortic
root disease with maximal ascending aortic diameter:
• >_45 mm in the presence of Marfan syndrome and
additional risk factorse or patients with a TGFBR1
or TGFBR2 mutation (including Loeys–Dietz
syndrome).f
• >_50 mm in the presence of a bicuspid valve with
additional risk factorse or coarctation.
• >_55 mm for all other patients.
IIa C
When surgery is primarily indicated for the aortic valve,
replacement of the aortic root or tubular ascending aorta
should be considered when >_45 mm, particularly in the
presence of a bicuspid valve.g
IIa C
BSA: body surface area; CABG: coronary artery bypass grafting; CT:
computed tomography; ECG: electrocardiogram; LV: left ventricular;
LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular
ejection fraction; LVESD: left ventricular end-systolic diameter.
aClass of recommendation.
bLevel of evidence.
cPatients with pliable non-calcified tricuspid or bicuspid valves who
have a type I (enlargement of the aortic root with normal cusp motion)
or type II (cusp prolapse) mechanism of aortic regurgitation [6, 48, 49].
dFor clinical decision making, dimensions of the aorta should be con-
firmed by ECG-gated CT measurement.
eFamily history of aortic dissection (or personal history of spontaneous
vascular dissection), severe aortic regurgitation or mitral regurgitation,
desire for pregnancy, systemic hypertension and/or aortic size increase
>3 mm/year (on repeated measurements using the same ECG-gated
imaging technique measured at the same level of the aorta with side-
by-side comparison and confirmed by another technique).
fA lower threshold of 40 mm may be considered in women with low
BSA, in patients with a TGFBR2 mutation or in patients with severe
extra-aortic features [60].
gConsidering age, BSA, aetiology of the valvular disease, presence of a
bicuspid aortic valve and intraoperative shape and thickness of the
ascending aorta.
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surgery should be considered at a maximal aortic diameter
>_45 mm [60]. In the latter group, women with low BSA, patients
with a TGFBR2 mutation or patients with severe extra-aortic fea-
tures appear to be at particularly high risk and surgery may be
considered already at a lower threshold of 40 mm [60]. In aortic
roots >_55 mm, surgery should be considered irrespective of the
degree of aortic regurgitation and type of valve pathology [61]. For
patients who have an indication for aortic valve surgery, an aortic
diameter >_45 mm is considered to indicate concomitant surgery of
the aortic root or tubular ascending aorta. The patient’s stature,
the aetiology of the valvular disease (bicuspid valve) and the intra-
operative shape and wall thickness of the ascending aorta should
be taken into account for individual decisions.
Although valve replacement is the standard procedure in the ma-
jority of patients with aortic regurgitation, valve repair or valve-
sparing surgery should be considered in patients with pliable non-
calcified tricuspid or bicuspid valves who have a type I (enlargement
of the aortic root with normal cusp motion) or type II (cusp pro-
lapse) mechanism of aortic regurgitation [6, 48, 49]. In experienced
centres, valve-sparing root replacement and valve repair, when feas-
ible, yield good long-term results with low rates of valve-related
events as well as better quality of life [62–65]. The choice of the sur-
gical procedure should be adapted to the experience of the team,
the presence of an aortic root aneurysm, characteristics of the cusps,
life expectancy and desired anticoagulation status. Patients in whom
the Heart Team identifies the aortic valve to be repairable should be
referred to appropriate surgical teams for the procedure.
4.3 Medical therapy
Medical therapy can provide symptomatic improvement in indi-
viduals with chronic severe aortic regurgitation in whom surgery
is not feasible. In patients who undergo surgery but continue to
suffer from heart failure or hypertension, angiotensin-converting
enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs)
and beta-blockers are useful [68, 69].
In patients with Marfan syndrome, beta-blockers and/or losar-
tan may slow aortic root dilatation and reduce the risk of aortic
complications and should be considered before and after surgery
[70–72]. By analogy, while there are no studies that provide evi-
dence, it is common clinical practice to advise beta-blocker or
losartan therapy in patients with bicuspid aortic valve if the aortic
root and/or ascending aorta is dilated.
Women with Marfan syndrome and an aortic diameter >45 mm
are strongly discouraged from becoming pregnant without prior
repair because of the high risk of dissection. Although an aortic
diameter <40 mm is rarely associated with aortic dissection, a
completely safe diameter does not exist. With an aorta between
40 and 45 mm, previous aortic growth and family history are im-
portant for advising pregnancy with or without aortic repair [73].
Although the actual risk of dissection is not well-documented in
the setting of bicuspid valves, counselling against pregnancy is rec-
ommended in the setting of aortic diameters >50 mm [74].
The level of physical and sports activity in the presence of a
dilated aorta remains a matter of clinical judgement in the absence
of evidence. Current guidelines are very restrictive, particularly re-
garding isometric exercise, to avoid a catastrophic event [75]. This at-
titude is clearly justified in the presence of connective tissue disease.
Given the family risk of thoracic aortic aneurysms, screening and
referral for genetic testing of the patient’s first-degree relatives with
appropriate imaging studies is indicated in patients with connective
tissue disease. For patients with bicuspid valves it is appropriate to
have an echocardiographic screening of first-degree relatives.
4.4 Serial testing
All asymptomatic patients with severe aortic regurgitation and
normal LV function should be seen for follow-up at least every
year. In patients with a first diagnosis, or if LV diameter and/or
ejection fraction show significant changes or come close to
thresholds for surgery, follow-up should be continued at 3–6-
month intervals. In inconclusive cases, BNP may be helpful, as its
elevation during follow-up has been related to deterioration of
LV function [76]. Patients with mild to moderate aortic regurgita-
tion can be reviewed on a yearly basis and echocardiography
performed every 2 years.
If the ascending aorta is dilated (>40 mm) it is recommended
to perform CT or CMR. Follow-up assessment of the aortic di-
mension should be performed using echocardiography and/or
CMR. Any increase >3 mm should be validated by CT angiog-
raphy/CMR and compared to baseline data.
4.5 Special patient populations
If aortic regurgitation requiring surgery is associated with severe
mitral regurgitation, both should be addressed during the same
operation.
In patients with moderate aortic regurgitation who undergo
coronary artery bypass grafting (CABG) or mitral valve surgery,
the decision to treat the aortic valve is controversial, as data
show that progression of moderate aortic regurgitation is very
slow in patients without aortic dilatation [77]. The Heart Team
should decide based on the aetiology of aortic regurgitation,
other clinical factors, the life expectancy of the patient and the
patient’s operative risk.
Key points
• The evaluation of aortic regurgitation requires consideration
of valve morphology and the mechanism and severity of re-
gurgitation, including careful assessment of aortic dilatation.
• In asymptomatic patients with severe aortic regurgitation,
careful follow-up of symptomatic status and LV size and func-
tion is mandatory.
• The strongest indication for valve surgery is the presence of
symptoms (spontaneous or on exercise testing) and/or the
documentation of LVEF <50% and/or end-systolic diameter
>50 mm.
• In patients with a dilated aorta, definition of the aortic path-
ology and accurate measurements of aortic diameters are cru-
cial to guide the timing and type of surgery.
• Aortic valve repair and valve-sparing aortic surgery instead of
aortic valve replacement should be considered in selected
cases in experienced centres.
Gaps in evidence
• The impact of earlier markers of LV dysfunction on postoper-
ative outcome requires further research.
• Criteria for the decision between valve replacement and valve
repair must still be refined.
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• Potential differences in the risk of aortic complications de-
pending on subtypes of aortic aneurysms (site and morph-
ology) should be studied.
• The effect of medical treatment on aortic enlargement in pa-
tients with bicuspid aortic valve needs to be studied.
5. AORTIC STENOSIS
Aortic stenosis is the most common primary valve disease leading
to surgery or catheter intervention in Europe and North America,
with a growing prevalence due to the ageing population.
5.1 Evaluation
5.1.1 Echocardiography. Echocardiography is the key diagnostic
tool. It confirms the presence of aortic stenosis; assesses the degree
of valve calcification, LV function and wall thickness; detects the
presence of other associated valve disease or aortic pathology and
provides prognostic information. Doppler echocardiography is the
preferred technique for assessing the severity of aortic stenosis [4].
Figure 2 and Table 6 provide a practical stepwise approach for
the assessment of aortic stenosis severity. Details can be found in
a recent position paper from the European Association of
Cardiovascular Imaging [4].
Figure 2: Stepwise integrated approach for the assessment of aortic stenosis severity (modified from Baumgartner et al. [4]). aHigh flow may be reversible in settings
such as anaemia, hyperthyroidism, arteriovenous shunts. bPseudosevere AS is defined by an increase to an AVA >1.0 cm2 with flow normalization.
DPm: mean transvalvular pressure gradient; AS: aortic stenosis; AVA: aortic valve area; CT: computed tomography; EF: ejection fraction; LVEF: left ventricular
ejection fraction; SVi: stroke volume index; Vmax: peak transvalvular velocity.
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Although valve area represents, from a theoretical perspec-
tive, the ideal measurement for assessing the severity of aor-
tic stenosis, it has technical limitations in clinical practice.
It must, for clinical decision making, always be considered
together with flow rate, mean pressure gradient (the most ro-
bust measurement), ventricular function, size and wall thickness,
degree of valve calcification, blood pressure and functional
status. Hypertensive patients should be reassessed when
normotensive [4]. Four categories of aortic stenosis can be
defined:
• High-gradient aortic stenosis (valve area <1 cm2, mean gradi-
ent >40 mmHg). Severe aortic stenosis can be assumed irre-
spective of whether LVEF and flow are normal or reduced.
• Low-flow, low-gradient aortic stenosis with reduced ejection
fraction [valve area <1 cm2, mean gradient <40 mmHg, ejec-
tion fraction <50%, stroke volume index (SVi) <_35 ml/m2].
Low-dose dobutamine echocardiography is recommended in
this setting to distinguish truly severe aortic stenosis from
pseudosevere aortic stenosis, which is defined by an increase
to an aortic valve area (AVA) of >1.0 cm2 with flow normaliza-
tion. In addition, the presence of flow reserve (also termed
contractile reserve; increase of stroke volume >20%) has prog-
nostic implications because it is associated with better out-
come [10, 78].
• Low-flow, low-gradient aortic stenosis with preserved ejection
fraction (valve area <1 cm2, mean gradient <40 mmHg, ejec-
tion fraction >_50%, SVi <_35 ml/m2). This is typically encoun-
tered in the elderly and is associated with small ventricular
size, marked LV hypertrophy and frequently a history of
hypertension [79,80]. The diagnosis of severe aortic stenosis in
this setting remains challenging and requires careful exclusion
of measurement errors and other reasons for such
echocardiographic findings (Table 6). The degree of valve cal-
cification by MSCT is related to aortic stenosis severity and
outcome [13,14,81]. Its assessment has therefore gained
increasing importance in this setting.
• Normal-flow, low-gradient aortic stenosis with preserved ejec-
tion fraction (valve area <1 cm2, mean gradient <40 mmHg,
ejection fraction >_50%, SVi >35 m2). These patients will in gen-
eral have only moderate aortic stenosis [14, 82–84].
5.1.2 Additional diagnostic aspects, including assessment
of prognostic parameters. Exercise testing is recommended
in physically active patients for unmasking symptoms and for
risk stratification of asymptomatic patients with severe aortic
stenosis [85].
Exercise stress echocardiography may provide prognostic in-
formation in asymptomatic severe aortic stenosis by assessing
the increase in mean pressure gradient and change in LV func-
tion during exercise [86].
TOE provides additional evaluation of concomitant mitral
valve abnormalities. It has gained importance in the assessment
before TAVI and after TAVI or surgical procedures [87].
MSCT and CMR provide additional information on the dimen-
sions and geometry of the aortic root and ascending aorta and
the extent of calcification. It has become particularly important
for the quantification of valve calcification when assessing aortic
stenosis severity in low-gradient aortic stenosis [13, 14, 81]. CMR
may be useful for the detection and quantification of myocardial
fibrosis, providing additional prognostic information regardless
of the presence of CAD [88].
Natriuretic peptides have been shown to predict symptom-
free survival and outcome in normal and low-flow severe aortic
stenosis [89, 90] and may be useful in asymptomatic patients to
determine optimal timing of intervention.
Table 6: Criteria that increase the likelihood of severe aortic stenosis in patients with AVA <1.0 cm2 and mean gradient <40 mmHg
in the presence of preserved ejection fraction (modified from Baumgartner et al. [4])
3D: three-dimensional; AVA: aortic valve area; CMR: cardiovascular magnetic resonance; LV: left ventricular; LVOT: left ventricular outflow tract; MSCT: multi-
slice computed tomography; SVi: stroke volume index; TOE: transoesophageal echocardiography.
aHaemodynamics measured when the patient is normotensive.
bValues are given in arbitrary units using Agatston method for quantification of valve calcification.
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Retrograde LV catheterization to assess the severity of aortic
stenosis is no longer routinely performed. Its use is restricted to
patients with inconclusive non-invasive investigations.
5.1.3 Diagnostic workup before transcatheter aortic valve
implantation. MSCT is the preferred imaging tool to assess the
anatomy and dimensions of the aortic root, size and shape of the
aortic valve annulus, its distance to the coronary ostia, the distribu-
tion of calcifications and the number of aortic valve cusps. It is es-
sential to evaluate the feasibility of the various access routes, as
this provides information on minimal luminal diameters, athero-
sclerotic plaque burden, the presence of aneurysms or thrombi,
vessel tortuosity and thoracic and LV apex anatomy. CMR—as an
alternative technique—is, in this context, inferior to MSCT with re-
gards to assessment of inner vessel dimensions and calcifications.
3D TOE can be used to determine aortic annulus dimensions but
remains more operator- and image quality–dependent than
MSCT. However, TOE is an important tool for monitoring the pro-
cedure and evaluating the results, especially if complications occur.
5.2 Indications for intervention
The indications for aortic valve interventions are summarized on
the next page (see table of indications for intervention in aortic
stenosis and recommendations for the choice of intervention
mode) and in Table 7 and are illustrated in Figure 3.
5.2.1 Indications for intervention in symptomatic aortic
stenosis. Early therapy should be strongly recommended in all
symptomatic patients with severe aortic stenosis because of their
dismal spontaneous prognosis. The only exceptions are patients
with severe comorbidities indicating a survival of < 1 year and pa-
tients in whom severe comorbidities or their general condition at
an advanced age make it unlikely that the intervention will im-
prove quality of life or survival.
As long as the mean gradient remains >40 mmHg, there is vir-
tually no lower ejection fraction limit for intervention, whether
surgery or TAVI. The management of patients with low-gradient
aortic stenosis is more challenging:
• In patients with low-flow, low-gradient aortic stenosis and
reduced ejection fraction in whom the depressed ejection
fraction is predominantly caused by excessive afterload, LV
function usually improves after intervention [10,104].
Conversely, improvement in LV function after intervention is
uncertain if the primary cause is scarring due to extensive
myocardial infarction or cardiomyopathy. Intervention is def-
initely advised when severe aortic stenosis is confirmed at
increasing flow (true severe aortic stenosis) [10], while pa-
tients who are classified as having pseudosevere aortic sten-
osis at increasing flow should receive conventional treatment
for heart failure [105]. Although the outcome of patients
without flow reserve is compromised by a higher operative
mortality, SAVR (as well as TAVI) has also been shown to im-
prove ejection fraction and clinical status in such patients
[10,78,104]. Decision making should take into account the
clinical condition (in particular the comorbidities), the degree
of valve calcification, the extent of coronary disease and the
feasibility of concomitant or staged revascularization. The
Table 7: Aspects to be considered by the Heart Team for
the decision between SAVR and TAVI in patients at increased
surgical risk (see Table of Recommendations in section 5.2.)
CABG: coronary artery bypass grafting; CAD: coronary artery disease;
EuroSCORE: European System for Cardiac Operative Risk Evaluation; LV:
left ventricle; SAVR: surgical aortic valve replacement; STS: Society of
Thoracic Surgeons; TAVI: transcatheter aortic valve implantation.
aSTS score (calculator: http://riskcalc.sts.org/stswebriskcalc/#/calculate);
EuroSCORE II (calculator: http://www.euroscore.org/calc.html); logistic
EuroSCORE I (calculator: http://www.euroscore.org/calcge.html); scores
have major limitations for practical use in this setting by insufficiently con-
sidering disease severity and not including major risk factors such as frailty,
porcelain aorta, chest radiation etc [103]. EuroSCORE I markedly overesti-
mates 30-day mortality and should therefore be replaced by the better per-
forming EuroSCORE II with this regard; it is nevertheless provided here for
comparison as it has been used in many TAVI studies/registries and may
still be useful to identify the subgroups of patients for decision between
intervention modalities and to predict 1-year mortality.
bSee section 3.3, general comments, for frailty assessment.
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Indications for intervention in aortic stenosis and recommendations for the choice of intervention mode
A) Symptomatic aortic stenosis Classa Levelb
Intervention is indicated in symptomatic patients with severe, high-gradient aortic stenosis (mean gradient >_40 mmHg or peak velocity
>_4.0 m/s) [91–93].
I B
Intervention is indicated in symptomatic patients with severe low-flow, low-gradient (<40 mmHg) aortic stenosis with reduced ejection
fraction and evidence of flow (contractile) reserve excluding pseudosevere aortic stenosis.
I C
Intervention should be considered in symptomatic patients with low-flow, low-gradient (<40 mmHg) aortic stenosis with normal ejection
fraction after careful confirmation of severe aortic stenosisc (see Figure 2 and Table 6).
IIa C
Intervention should be considered in symptomatic patients with low-flow, low-gradient aortic stenosis and reduced ejection fraction with-
out flow (contractile) reserve, particularly when CT calcium scoring confirms severe aortic stenosis.
IIa C
Intervention should not be performed in patients with severe comorbidities when the intervention is unlikely to improve quality of life or
survival.
III C
B) Choice of intervention in symptomatic aortic stenosis
Aortic valve interventions should only be performed in centres with both departments of cardiology and cardiac surgery on site and with
structured collaboration between the two, including a Heart Team (heart valve centres).
I C
The choice for intervention must be based on careful individual evaluation of technical suitability and weighing of risks and benefits of
each modality (aspects to be considered are listed in Table 7). In addition, the local expertise and outcomes data for the given intervention
must be taken into account.
I C
SAVR is recommended in patients at low surgical risk (STS or EuroSCORE II <4% or logistic EuroSCORE I <10%d and no other risk factors
not included in these scores, such as frailty, porcelain aorta, sequelae of chest radiation) [93].
I B
TAVI is recommended in patients who are not suitable for SAVR as assessed by the Heart Team [91, 94]. I B
In patients who are at increased surgical risk (STS or EuroSCORE II >_ 4% or logistic EuroSCORE I >_ 10%d or other risk factors not included in
these scores such as frailty, porcelain aorta, sequelae of chest radiation), the decision between SAVR and TAVI should be made by the
Heart Team according to the individual patient characteristics (see Table 7), with TAVI being favoured in elderly patients suitable for trans-
femoral access [91, 94–102].
I B
Balloon aortic valvotomy may be considered as a bridge to SAVR or TAVI in haemodynamically unstable patients or in patients with symp-
tomatic severe aortic stenosis who require urgent major non-cardiac surgery.
IIb C
Balloon aortic valvotomy may be considered as a diagnostic means in patients with severe aortic stenosis or other potential causes for
symptoms (i.e. lung disease) and in patients with severe myocardial dysfunction, pre-renal insufficiency or other organ dysfunction that
may be reversible with balloon aortic valvotomy when performed in centres that can escalate to TAVI.
IIb C
C) Asymptomatic patients with severe aortic stenosis (refers only to patients eligible for surgical valve replacement)
SAVR is indicated in asymptomatic patients with severe aortic stenosis and systolic LV dysfunction (LVEF <50%) not due to another cause. I C
SAVR is indicated in asymptomatic patients with severe aortic stenosis and an abnormal exercise test showing symptoms on exercise
clearly related to aortic stenosis.
I C
SAVR should be considered in asymptomatic patients with severe aortic stenosis and an abnormal exercise test showing a decrease in
blood pressure below baseline.
IIa C
SAVR should be considered in asymptomatic patients with normal ejection fraction and none of the above-mentioned exercise test abnor-
malities if the surgical risk is low and one of the following findings is present:
• Very severe aortic stenosis defined by a Vmax >5.5 m/s
• Severe valve calcification and a rate of Vmax progression >_0.3 m/s/year
• Markedly elevated BNP levels (>threefold age- and sex-corrected normal range) confirmed by repeated measurements with-
out other explanations
• Severe pulmonary hypertension (systolic pulmonary artery pressure at rest >60 mmHg confirmed by invasive measurement)
without other explanation.
IIa C
Continued
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D) Concomitant aortic valve surgery at the time of other cardiac/ascending aorta surgery
SAVR is indicated in patients with severe aortic stenosis undergoing CABG or surgery of the ascending aorta or of another valve. I C
SAVR should be considered in patients with moderate aortic stenosise undergoing CABG or surgery of the ascending aorta or of another
valve after Heart Team decision.
IIa C
BNP: B-type natriuretic peptide; CABG, coronary artery bypass grafting; CT: computed tomography; EuroSCORE: European System for Cardiac Operative Risk
Evaluation; LV: left ventricular; LVEF: left ventricular ejection fraction; SAVR: surgical aortic valve replacement; STS: Society of Thoracic Surgeons; TAVI: trans-
catheter aortic valve implantation; Vmax: peak transvalvular velocity.
aClass of recommendation.
bLevel of evidence.
cIn patients with a small valve area but low gradient despite preserved LVEF, explanations for this finding other than the presence of severe aortic stenosis are
frequent and must be carefully excluded. See Figure 2 and Table 6.
dSTS score (calculator: http://riskcalc.sts.org/stswebriskcalc/#/calculate); EuroSCORE II (calculator: http://www.euroscore.org/calc.html); logistic EuroSCORE I (cal-
culator: http://www.euroscore.org/calcge.html); scores have major limitations for practical use in this setting by insufficiently considering disease severity and not
including major risk factors such as frailty, porcelain aorta, chest radiation, etc [103]. EuroSCORE I markedly overestimates 30-day mortality and should therefore
be replaced by the better-performing EuroSCORE II with this regard; it is nevertheless provided here for comparison, as it has been used in many TAVI studies/
registries and may still be useful to identify the subgroups of patients for decision between intervention modalities and to predict 1-year mortality.
eModerate aortic stenosis is defined as a valve area of 1.0–1.5 cm2 or a mean aortic gradient of 25–40 mmHg in the presence of normal flow conditions.
However, clinical judgement is required.
Figure 3: Management of severe aortic stenosis. AS: aortic stenosis; LVEF: left ventricular ejection fraction; SAVR: surgical aortic valve replacement; TAVI: transcatheter
aortic valve implantation.
aSee Figure 2 and Table 6 for the definition of severe AS. bSurgery should be considered (IIa C) if one of the following is present: peak velocity >5.5 m/s; se-
vere valve calcification + peak velocity progression >_0.3 m/s per year; markedly elevated neurohormones (>threefold age- and sex-corrected normal range)
without other explanation; severe pulmonary hypertension (systolic pulmonary artery pressure >60 mmHg). cSee Table 7 and Table of Recommendations in
section 5.2 Indications for interventions in aortic stenosis.
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ability to identify patients with severe aortic stenosis in this
subgroup by CT calcium scoring and the availability of TAVI
have lowered the threshold to intervene.
• Patients with low-flow, low-gradient aortic stenosis and pre-
served ejection fraction are the most challenging subgroup.
Data on their natural history and outcome after surgical or
catheter intervention remain controversial [80, 83, 84]. In such
cases, intervention should only be performed when symp-
toms are present and if comprehensive evaluation suggests
significant valve obstruction (see Figure 2 and Table 6).
• Patients with normal-flow, low-gradient aortic stenosis and
preserved ejection fraction data should be re-evaluated. If
normal flow and low gradient are confirmed, these patients
will, in general, not have severe aortic stenosis and do not
benefit from intervention [82, 83].
5.2.2 Choice of intervention mode in symptomatic aortic
stenosis. The choice of the intervention mode should take into
account the cardiac and extracardiac characteristics of the pa-
tient, the individual risk of surgery, which is assessed by the
judgement of the Heart Team in addition to scores, the feasibility
of TAVI and the local experience and outcome data.
Data on TAVI are still very limited for patients <75 years of age
and for surgical low-risk patients, in whom SAVR remains the ref-
erence method. It has to be emphasized that younger patients
differ with regard to anatomy (more bicuspid valves), which af-
fects the results of TAVI (bicuspid valves were also in general
excluded in clinical trials), and that long-term durability data for
TAVI prosthetic valves are still lacking.
Available data from randomized controlled trials and large regis-
tries in elderly patients at increased surgical risk show that TAVI is
superior in terms of mortality to medical therapy in extreme-risk
patients [91], non-inferior or superior to surgery in high-risk pa-
tients [94–97] and non-inferior to surgery and even superior
when transfemoral access is possible in intermediate-risk patients
[98–102]. In the two large studies on intermediate risk, the mean
ages of patients were 82 and 80 years [99, 102], mean STS scores
were 5.8% and 4.5% [99, 102] and a high percentage were con-
sidered frail. Thus the results are valid only for comparable patient
groups. Overall, rates of vascular complications, pacemaker im-
plantation and paravalvular regurgitation were significantly higher
for TAVI, while the degree of excess depended on the device used
[101, 102]. On the other hand, severe bleeding, acute kidney injury
and new-onset atrial fibrillation were significantly more frequent
with surgery, whereas no difference was observed in the rate of
cerebrovascular events [101, 102]. The favourable results of TAVI
have been reproduced in multiple large-scale, nationwide registries
supporting the generalizability of outcomes observed in random-
ized controlled trials. This favours the use of TAVI over surgery in
elderly patients at increased surgical risk. However, the final deci-
sion between SAVR and TAVI (including the choice of access route)
should be made by the Heart Team after careful individual evalu-
ation. Table 7 provides aspects that should be considered for the
individual decision. Balloon valvuloplasty may be considered as a
bridge to surgery or TAVI, or diagnostically.
5.2.3 Asymptomatic aortic stenosis. Management of asymp-
tomatic severe aortic stenosis remains controversial. The available
studies do not provide convincing data to support the general
recommendation of early SAVR, even in patients with asymptom-
atic very severe aortic stenosis [92, 106]. The decision to operate
on asymptomatic patients requires careful weighing of the benefits
against the risks. This section refers only to patients who are candi-
dates for SAVR, as TAVI is not recommended in asymptomatic pa-
tients. Early elective surgery is indicated in asymptomatic patients
with depressed LV function not due to other causes and in patients
who develop symptoms during exercise testing [85, 107].
Predictors of symptom development and adverse outcomes in
asymptomatic patients include clinical characteristics (older age,
presence of atherosclerotic risk factors), echocardiographic param-
eters (valve calcification, peak aortic jet velocity [92, 108], LVEF, rate
of haemodynamic progression [92], increase in mean gradient
>20 mmHg with exercise [86], excessive LV hypertrophy [109], ab-
normal longitudinal LV function [110] and pulmonary hypertension
[111]) and biomarkers (elevated plasma levels of natriuretic pep-
tides, although the precise cut-off values have not yet been well
defined [89, 90]). When early elective surgery is considered in pa-
tients with normal exercise performance because of the presence of
such outcome predictors, the operative risk should be low (see table
of recommendations in section 5.2 Indications for interventions in
aortic stenosis). In patients without predictive factors, watchful wait-
ing appears safe and early surgery is unlikely to be beneficial.
5.3 Medical therapy
No medical therapy for aortic stenosis can improve outcome com-
pared with the natural history. Randomized trials have consistently
shown that statins do not affect the progression of aortic stenosis
[112]. Patients with symptoms of heart failure who are unsuitable
candidates for surgery or TAVI or who are currently awaiting surgi-
cal or catheter intervention should be medically treated according
to the heart failure guidelines [113]. Coexisting hypertension
should be treated. Medical treatment should be carefully titrated
to avoid hypotension and patients should be re-evaluated fre-
quently. Maintenance of sinus rhythm is important.
5.4 Serial testing
In the asymptomatic patient, the wide variability in the rate of
progression of aortic stenosis stresses the need for patients to be
carefully educated about the importance of follow-up and re-
porting symptoms as soon as they develop. Stress tests should
determine the recommended level of physical activity. Follow-up
evaluation should focus on haemodynamic progression, LV func-
tion and hypertrophy and dimensions of the ascending aorta.
Asymptomatic severe aortic stenosis should be re-evaluated
at least every 6 months for the occurrence of symptoms (change
in exercise tolerance, ideally using exercise testing if symptoms
are doubtful) and change in echocardiographic parameters.
Measurement of natriuretic peptides should be considered.
In the presence of significant calcification, mild and moderate
aortic stenosis should be re-evaluated yearly. In younger patients
with mild aortic stenosis and no significant calcification, intervals
may be extended to 2–3 years.
5.5 Special patient populations
Combined SAVR and CABG carry a higher risk than isolated SAVR.
However, SAVR late after CABG is also associated with significantly
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increased risk. Data from retrospective analyses indicate that pa-
tients in whom CABG is indicated and who have moderate aortic
stenosis will in general benefit from concomitant SAVR. It has also
been suggested that if age is <70 years and, more importantly, an
average rate of aortic stenosis progression of 5 mmHg/year is
documented, patients may benefit from valve replacement at the
time of coronary surgery once the baseline peak gradient exceeds
30 mmHg [114]. Individual judgement is recommended, taking
into consideration BSA, haemodynamic data, leaflet calcification,
aortic stenosis progression rate, patient life expectancy and associ-
ated comorbidities, as well as the individual risk of either concomi-
tant valve replacement or late reoperation [93]. Patients with
severe symptomatic aortic stenosis and diffuse CAD that cannot
be revascularized should not be denied SAVR or TAVI.
Combined PCI and TAVI has been shown to be feasible but re-
quires more data before a firm recommendation can be made.
The chronology of interventions should be the subject of individ-
ualized discussion based on the patient’s clinical condition, extent
of CAD and myocardium at risk.
When mitral regurgitation is associated with severe aortic sten-
osis, its severity may be overestimated in the presence of the high
ventricular pressures and careful quantification is required. As long
as there are no morphological leaflet abnormalities (flail or pro-
lapse, post-rheumatic changes or signs of infective endocarditis),
mitral annulus dilatation or marked abnormalities of LV geometry,
surgical intervention on the mitral valve is in general not neces-
sary. Non-severe secondary mitral regurgitation mostly improves
after the aortic valve is treated. In patients with severe mitral re-
gurgitation, combined or sequential TAVI and percutaneous mitral
edge-to-edge repair have been demonstrated to be feasible, but
there is not enough experience to make recommendations.
Concomitant aneurysm/dilatation of the ascending aorta re-
quires the same treatment as in aortic regurgitation (see section 4).
For congenital aortic stenosis, see the ESC guidelines on
grown-up congenital heart disease [115].
Key points
• The diagnosis of severe aortic stenosis requires consideration
of AVA together with flow rate, pressure gradients (the most
robust measurement), ventricular function, size and wall thick-
ness, degree of valve calcification and blood pressure, as well
as functional status.
• The assessment of the severity of aortic stenosis in patients
with low gradient and preserved ejection fraction remains
particularly challenging.
• The strongest indication for intervention remains symptoms
of aortic stenosis (spontaneous or on exercise testing).
• The presence of predictors of rapid symptom development
can justify early surgery in asymptomatic patients, particularly
when surgical risk is low.
• Although current data favour TAVI in elderly patients who are
at increased risk for surgery, particularly when a transfemoral
access is possible, the decision between TAVI and SAVR should
be made by the Heart Team after careful, comprehensive evalu-
ation of the patient, weighing individually the risks and benefits.
Gaps in evidence
• The impact of earlier markers of LV dysfunction on postoper-
ative outcome requires further research.
• The identification of patients with low-gradient aortic stenosis
who have severe stenosis and would benefit from interven-
tion requires improvement.
• The criteria for identification of patients who would benefit
from early elective surgery in asymptomatic severe aortic
stenosis requires further research.
• Long-term follow-up after TAVI is required; in particular, the
long-term durability of the valves needs to be studied.
• Criteria for the decision between TAVI and SAVR in patients
at increased operative risk who are eligible for both must be
refined and must be studied in surgical low-risk patients.
• Criteria for when TAVI should no longer be performed since
it would be futile need to be further defined.
6. MITRAL REGURGITATION
Mitral regurgitation is the second-most frequent indication for
valve surgery in Europe [47]. It is essential to distinguish primary
from secondary mitral regurgitation, particularly regarding surgi-
cal and transcatheter interventional management [116].
6.1 Primary mitral regurgitation
In primary mitral regurgitation, one or several components of
the mitral valve apparatus are directly affected. The most fre-
quent aetiology is degenerative (prolapse, flail leaflet).
Endocarditis as one of the causes of primary mitral regurgitation
is discussed in specific ESC guidelines [28].
6.1.1 Evaluation. Echocardiography is the principal investigation
used to assess the severity and mechanism of mitral regurgitation,
its consequences for the LV (function and remodelling), left atrium
(LA) and pulmonary circulation, as well as the likelihood of repair.
Quantification should be performed in an integrative way,
including qualitative, semi-quantitative and quantitative param-
eters. The criteria for defining severe primary mitral regurgitation
are summarized in Table 4 [2, 7].
A precise anatomical description of the lesions, using the segmen-
tal and functional anatomy according to the Carpentier classification
[2, 7] should be performed to assess the feasibility of repair. TTE also
assesses mitral annular dimensions and the presence of calcification.
TTE is diagnostic in most cases, but TOE is recommended, par-
ticularly in the presence of suboptimal image quality [117].
Three-dimensional echocardiography provides additional infor-
mation for selecting the appropriate repair strategy.
The consequences of mitral regurgitation on ventricular function
are assessed by measuring LV size and ejection fraction. LA volume,
systolic pulmonary artery pressure, tricuspid regurgitation and an-
nular size and RV function are important additional parameters.
Determination of functional capacity and symptoms assessed
by cardiopulmonary exercise testing may be useful in asymptom-
atic patients. Exercise echocardiography is useful to quantify
exercise-induced changes in mitral regurgitation [118], in systolic
pulmonary artery pressure and in LV function. It may be particu-
larly helpful in patients with symptoms and uncertainty about
the severity of mitral regurgitation based on measurements at
rest. In asymptomatic patients, the significant increase of pul-
monary artery pressure with exercise (>60 mmHg) has been re-
ported to be of prognostic value [119]. The use of global
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longitudinal strain could be of potential interest for the detection
of subclinical LV dysfunction but is limited by inconsistent algo-
rithms used by different echocardiographic systems.
Neurohormonal activation is observed in mitral regurgitation,
with a potential value of elevated BNP levels and a change in BNP
as predictors of outcome (particularly of symptom onset). In par-
ticular, low plasma BNP has a high negative predictive value and
may be helpful in the follow-up of asymptomatic patients [120].
As echocardiographic measures of pulmonary pressure may
show disagreement with invasive measures, the measurement
should be invasively confirmed by right-heart catheterization if
this is the only indication for surgery.
6.1.2 Indications for intervention. Urgent surgery is indicated
in patients with acute severe mitral regurgitation. In the case of
papillary muscle rupture as the underlying disease, valve replace-
ment is in general required.
Indications for surgery in severe chronic primary mitral regurgita-
tion are shown in the following table of recommendations (indica-
tions for intervention in severe primary mitral regurgitation) and in
Figure 4. Surgery is obviously indicated in symptomatic patients with
severe primary mitral regurgitation [121]. An LVEF <_60% or LVESD
>_45 mm [122], atrial fibrillation [123] and a systolic pulmonary pres-
sure >_50 mmHg [124] predict a worse postoperative outcome inde-
pendent of the symptomatic status and have therefore become
triggers for surgery in asymptomatic patients. In patients with flail leaf-
let, an LVESD of 40–44 mm has been reported to predict a worse out-
come compared with LVESD <40 mm [125]. Significant LA dilatation
despite sinus rhythm has also been found to be a predictor of out-
come [124]. In the presence of these two latter triggers, surgery should
only be considered in heart valve centres and if surgical risk is low. An
increase in systolic pulmonary artery pressure >60 mmHg on exercise
echocardiography has also been proposed for risk stratification [119].
However, criteria that may indicate surgery have not been sufficiently
well defined to be included in the current recommendations.
Watchful waiting is a safe strategy in asymptomatic patients
with severe primary mitral regurgitation and none of the above
indications for surgery [126], and ideally patients are followed in
the setting of a heart valve centre [32].
Despite the absence of a randomized comparison between the
results of valve replacement and repair, it is widely accepted that,
when feasible, valve repair is the preferred treatment. Achieving
a durable valve repair is essential. Degenerative mitral regurgita-
tion due to segmental valve prolapse can be repaired with a low
risk of mitral regurgitation recurrence and reoperation. The rep-
arability of rheumatic lesions, extensive valve prolapse and—even
more so—mitral regurgitation with leaflet calcification or exten-
sive annular calcification is more challenging. Patients with a pre-
dictably complex repair should undergo surgery in experienced
repair centres with high repair rates, low operative mortality and
a record of durable results [127, 128]. When repair is not feasible,
mitral valve replacement with preservation of the subvalvular ap-
paratus is favoured. Additional tricuspid valve repair should be
performed as indicated in section 8.2 (see table of recommenda-
tions on indications for tricuspid valve surgery).
Transcatheter mitral valve interventions have been developed
to correct primary mitral regurgitation either through a transsep-
tal or a transapical approach. Among the transcatheter proced-
ures, currently only the edge-to-edge mitral repair is widely
adopted [129]. Experience with transcatheter annuloplasty, trans-
apical chordal implantation or valve replacement is still limited
and general recommendations cannot yet be made.
Transcatheter mitral valve treatment should be discussed by the
Heart Team in symptomatic patients who are at high surgical risk
or are inoperable. Percutaneous edge-to-edge repair is generally
safe and can improve symptoms and provide reverse LV remod-
elling. However, the rate of residual mitral regurgitation up to
5 years is higher than with surgical repair [130].
Indications for intervention in severe primary mitral
regurgitation
Recommendations Classa Levelb
Mitral valve repair should be the preferred
technique when the results are expected to
be durable.
I C
Surgery is indicated in symptomatic
patients with LVEF >30% [121, 131, 132].
I B
Surgery is indicated in asymptomatic
patients with LV dysfunction (LVESD
>_45 mmc and/or LVEF <_60%) [122, 131].
I B
Surgery should be considered in asympto-
matic patients with preserved LV function
(LVESD <45 mm and LVEF >60%) and atrial
fibrillation secondary to mitral regurgitation
or pulmonary hypertensiond (systolic pulmo-
nary pressure at rest >50 mmHg) [123, 124].
IIa B
Surgery should be considered in asympto-
matic patients with preserved LVEF (>60%)
and LVESD 40–44 mmc when a durable
repair is likely, surgical risk is low, the repair is
performed in a heart valve centre and at least
one of the following findings is present:
• flail leaflet or
• presence of significant LA dilatation (vol-
ume index >_60 ml/m2 BSA) in sinus rhythm.
IIa C
Mitral valve repair should be considered in
symptomatic patients with severe LV dys-
function (LVEF <30% and/or LVESD
>55 mm) refractory to medical therapy
when the likelihood of successful repair is
high and comorbidity low.
IIa C
Mitral valve replacement may be consid-
ered in symptomatic patients with severe
LV dysfunction (LVEF <30% and/or LVESD
>55 mm) refractory to medical therapy
when the likelihood of successful repair is
low and comorbidity low.
IIb C
Percutaneous edge-to-edge procedure may
be considered in patients with symptomatic
severe primary mitral regurgitation who fulfil
the echocardiographic criteria of eligibility
and are judged inoperable or at high surgical
risk by the Heart Team, avoiding futility.
IIb C
BSA: body surface area; LA: left atrial; LV: left ventricular; LVEF: left ven-
tricular ejection fraction; LVESD: left ventricular end-systolic diameter;
SPAP: systolic pulmonary artery pressure.
aClass of recommendation.
bLevel of evidence.
cCut-offs refer to average-size adults and may require adaptations in
patients with unusually small or large stature.
dIf an elevated SPAP is the only indication for surgery, the value should
be confirmed by invasive measurement.
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6.1.3 Medical therapy. In acute mitral regurgitation, nitrates
and diuretics are used to reduce filling pressures. Sodium nitro-
prusside reduces afterload and regurgitant fraction. Inotropic
agents and an intra-aortic balloon pump are of use in hypoten-
sion and haemodynamic instability.
In chronic mitral regurgitation with good ventricular function,
there is no evidence to support the prophylactic use of vasodila-
tors, including ACE inhibitors. However, ACE inhibitors should be
considered when heart failure has developed in patients who are
not suitable for surgery or when symptoms persist after surgery.
Beta-blockers and spironolactone (or eplerenone) should also be
considered as appropriate.
6.1.4 Serial testing. Asymptomatic patients with severe mitral
regurgitation and LVEF >60% should be followed clinically
and echocardiographically every 6 months, ideally in the setting
of a heart valve centre. Closer follow-up is indicated if no pre-
vious evaluation is available and when measured variables show
significant dynamic changes or are close to the thresholds.
When guideline indications for surgery are reached,
early surgery—within 2 months—is associated with better out-
comes [133]. Asymptomatic patients with moderate mitral re-
gurgitation and preserved LV function can be followed on a
yearly basis and echocardiography should be performed every
1–2 years.
6.2 Secondary mitral regurgitation
In secondary mitral regurgitation (previously also referred to as
‘functional mitral regurgitation’), the valve leaflets and chordae
are structurally normal and mitral regurgitation results from an
imbalance between closing and tethering forces on the valve sec-
ondary to alterations in LV geometry [134]. It is most commonly
seen in dilated or ischaemic cardiomyopathies. Annular dilatation
in patients with chronic atrial fibrillation and LA enlargement can
also be an underlying mechanism.
6.2.1 Evaluation. Echocardiography is essential to establish the
diagnosis of secondary mitral regurgitation. In secondary mitral
Figure 4: Management of severe chronic primary mitral regurgitation. AF: atrial fibrillation; BSA: body surface area; CRT: cardiac resynchronization therapy; HF: heart
failure; LA: left atrial; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic diameter; SPAP: systolic pulmonary arterial pressure.
aWhen there is a high likelihood of durable valve repair at a low-risk, valve repair should be considered (IIa C) in patients with LVESD >_40 mm and one of the
following is present: flail leaflet or LA volume >_60 ml/m2 BSA at sinus rhythm.
bExtended HF management includes the following: CRT; ventricular assist devices; cardiac restraint devices; heart transplantation.
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regurgitation, lower thresholds have been proposed to define se-
vere mitral regurgitation compared with primary mitral regurgi-
tation [20 mm2 for effective regurgitant orifice area (EROA) and
30 ml for regurgitant volume], owing to their association with
prognosis [135]. However, it is unclear if prognosis is independ-
ently affected by mitral regurgitation compared with LV dysfunc-
tion. So far, no survival benefit has been confirmed for reduction
of secondary mitral regurgitation.
For isolated mitral valve treatment (surgery or percutaneous
edge-to-edge repair) in secondary mitral regurgitation, thresh-
olds of severity of mitral regurgitation for intervention still need
to be validated in clinical trials. The severity of secondary mitral
regurgitation should be reassessed after optimized medical treat-
ment. The severity of tricuspid regurgitation and RV size and
function should also be evaluated.
Secondary mitral regurgitation is a dynamic condition; echo-
cardiographic quantification of mitral regurgitation during exer-
cise may provide prognostic information of dynamic
characteristics. Myocardial viability testing may be useful in pa-
tients with ischaemic secondary mitral regurgitation who are
candidates for revascularization.
6.2.2 Indications for intervention. The presence of chronic
secondary mitral regurgitation is associated with impaired prog-
nosis [135]. However, in contrast to primary mitral regurgitation,
there is currently no evidence that a reduction of secondary mi-
tral regurgitation improves survival. The limited data regarding
secondary mitral regurgitation result in a lower level of evidence
for treatment recommendations (see table of recommendations
on indications for mitral valve intervention in chronic secondary
mitral regurgitation) and highlight the importance of decision
making by the Heart Team. Heart failure and electrophysiology
specialists should be involved.
In patients with CAD undergoing revascularization, the evalu-
ation and decision to treat (or not to treat) ischaemic mitral re-
gurgitation should be made before surgery, as general
anaesthesia may significantly reduce the severity of regurgitation.
When mitral regurgitation severity is assessed intraoperatively,
the use of acute volume challenge and an increase in afterload
may be helpful.
The optimal surgical approach remains controversial [136].
While mitral valve repair with an undersized complete ring to re-
store leaflet coaptation and valve competence is the preferred
technique, valve replacement should be considered in patients
with echocardiographic risk factors for residual or recurrent mi-
tral regurgitation [2].
Indications for surgery in secondary mitral regurgitation are
particularly restrictive when concomitant revascularization is not
an option, owing to significant operative mortality, high rates of
recurrent mitral regurgitation and the absence of a proven sur-
vival benefit [137, 138].
Percutaneous edge-to-edge repair for secondary mitral regur-
gitation is a low-risk option, but its efficacy to reduce mitral re-
gurgitation remains inferior to surgery [139]. It can improve
symptoms, functional capacity and quality of life and may induce
reverse LV remodelling [140]. Similar to surgery, a survival benefit
compared with ‘optimal’ medical therapy according to current
guidelines [113] has not yet been proven.
In patients with markedly reduced LV function (ejection frac-
tion <_30%) and no option for revascularization who remain
symptomatic despite optimal heart-failure treatment [including
cardiac resynchronization therapy (CRT) when indicated], the de-
cision between palliative mitral regurgitation treatment—cath-
eter-based or surgical, ventricular assist devices, heart
transplantation—and continued conservative therapy should be
made by the Heart Team after careful individual evaluation of
the patient. Valve intervention is generally not an option when
the ejection fraction is <15%.
There is continuing debate regarding the management of
moderate ischaemic mitral regurgitation in patients undergoing
CABG. A recent randomized controlled trial could not show a
benefit of concomitant valve surgery [141]. Surgery is more
likely to be considered if myocardial viability is present and if
comorbidity is low. In patients capable of exercising, exercise-
induced dyspnoea and a large increase in mitral regurgitation
severity and systolic pulmonary artery pressure favour com-
bined surgery.
Indications for mitral valve intervention in chronic
secondary mitral regurgitationa
Recommendations Classb Levelc
Surgery is indicated in patients with severe
secondary mitral regurgitation undergoing
CABG and LVEF >30%.
I C
Surgery should be considered in sympto-
matic patients with severe secondary mitral
regurgitation, LVEF <30% but with an option
for revascularization and evidence of myo-
cardial viability.
IIa C
When revascularization is not indicated, sur-
gery may be considered in patients with
severe secondary mitral regurgitation and
LVEF >30% who remain symptomatic despite
optimal medical management (including
CRT if indicated) and have a low surgical risk.
IIb C
When revascularization is not indicated and
surgical risk is not low, a percutaneous edge-
to-edge procedure may be considered in
patients with severe secondary mitral regur-
gitation and LVEF >30% who remain sympto-
matic despite optimal medical management
(including CRT if indicated) and who have a
suitable valve morphology by echocardiog-
raphy, avoiding futility.
IIb C
In patients with severe secondary mitral
regurgitation and LVEF <30% who remain
symptomatic despite optimal medical man-
agement (including CRT if indicated) and
who have no option for revascularization,
the Heart Team may consider a
percutaneous edge-to-edge procedure or
valve surgery after careful evaluation for a
ventricular assist device or heart transplant
according to individual patient
characteristics.
IIb C
CABG: coronary artery bypass grafting; CRT: cardiac resynchronization
therapy; LVEF: left ventricular ejection fraction.
aSee section 6.2.1 for quantification of secondary mitral regurgitation,
which must always be performed under optimal treatment.
bClass of recommendation.
cLevel of evidence.
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6.2.3 Medical therapy. Optimal medical therapy in line with
the guidelines for the management of heart failure [113] should
be the first step in the management of all patients with secondary
mitral regurgitation. Indications for CRT should be evaluated in
accordance with related guidelines [113]. If symptoms persist
after optimization of conventional heart failure therapy, options
for mitral valve intervention should be evaluated.
Key points
• Echocardiography is essential to assess the aetiology of mitral
regurgitation, as well as valve anatomy and function. An inte-
grative approach is needed to assess the severity of mitral
regurgitation.
• Indication for intervention in primary mitral regurgitation is
guided by symptoms and risk stratification that includes the
assessment of ventricular function and size, atrial fibrillation,
systolic pulmonary pressure and LA size.
• In secondary mitral regurgitation, there is no conclusive evi-
dence for a survival benefit after mitral valve intervention.
Mitral surgery is recommended concomitantly in patients
with an indication for CABG and may be considered in pa-
tients who are symptomatic despite optimal medical therapy
(including CRT if indicated) or who have a low surgical risk
when revascularization is not indicated.
• Mitral valve repair is the preferred method, but mitral valve
replacement should be considered in patients with unfavour-
able morphological characteristics.
• Outcomes of mitral valve repair depend on surgeon experi-
ence and centre-related volume.
• Percutaneous edge-to-edge repair may be considered in pa-
tients at high surgical risk, avoiding futility.
Gaps in evidence
• The potential role of elective mitral valve surgery in asymp-
tomatic patients with severe primary mitral regurgitation with
preserved ventricular size and function who are in sinus
rhythm and have not developed a high pulmonary artery
pressure requires investigation in a randomized controlled
trial.
• The impact of earlier markers of LV dysfunction on postoper-
ative outcome requires further research.
• The thresholds to define severe secondary mitral regurgitation
are controversial and need to be evaluated with regards to
their impact on prognosis after mitral valve intervention.
• The potential impact of mitral valve intervention (surgery and
catheter intervention) on survival in patients with secondary
mitral regurgitation needs to be evaluated.
• The new percutaneous valve repair and valve implantation
techniques require further evaluation.
7. MITRAL STENOSIS
The incidence of rheumatic mitral stenosis has greatly decreased
in industrialized countries [142]. Degenerative calcific mitral valve
disease is now encountered mainly in elderly patients [143].
Percutaneous mitral commissurotomy (PMC) has had a signifi-
cant impact on the management of rheumatic mitral stenosis.
7.1 Evaluation
Echocardiography is the preferred method for diagnosing mitral
stenosis and for assessing its severity and haemodynamic conse-
quences. However, several specific issues should be considered.
Valve area using planimetry is the reference measurement of mi-
tral stenosis severity, whereas mean transvalvular gradient and pul-
monary pressures reflect its consequences and have a prognostic
value [3]. TTE usually provides sufficient information for routine
management. Scoring systems have been developed to help assess
suitability for PMC [144–146]. TOE should be performed to exclude
LA thrombus before PMC or after an embolic episode.
Echocardiography also plays an important role in monitoring the
results of PMC during the procedure. Stress testing is indicated in
patients with no symptoms or symptoms equivocal or discordant
with the severity of mitral stenosis. Exercise echocardiography may
provide additional objective information by assessing changes in
mitral gradient and pulmonary artery pressure.
7.2 Indications for intervention
The type of treatment, as well as its timing, should be decided on
the basis of clinical characteristics, valve anatomy and local expert-
ise. In general, indication for intervention should be limited to pa-
tients with clinically significant (moderate to severe) mitral stenosis
(valve area <1.5 cm2). However, PMC may be considered in symp-
tomatic patients with a valve area >1.5 cm2 if symptoms cannot be
explained by another cause and if the anatomy is favourable.
The management of clinically significant mitral stenosis is sum-
marized in Figure 5 and the indications and contraindications for
PMC are provided in the table of recommendations on indica-
tions for PMC and mitral valve surgery in clinically significant mi-
tral stenosis and in Table 8. Intervention should be performed in
symptomatic patients. Most patients with favourable valve anat-
omy currently undergo PMC, however, open commissurotomy
may be preferred by experienced surgeons in young patients
with mild to moderate mitral regurgitation.
In patients with unfavourable anatomy, decision making as to
the type of intervention is still a matter of debate and must take
into account the multifactorial nature of predicting the results of
PMC [147–149]. PMC should be considered as an initial treat-
ment for selected patients with mild to moderate calcification or
impaired subvalvular apparatus who have otherwise favourable
clinical characteristics. Surgery, which is mostly valve replace-
ment, is indicated in the other patients.
Owing to the small but definite risk inherent to PMC, truly
asymptomatic patients, as assessed using stress testing, are usu-
ally not candidates for the procedure, except in cases where
there is increased risk of systemic embolism or haemodynamic
decompensation. In such patients, PMC should only be per-
formed if they have favourable characteristics and if it is under-
taken by experienced operators.
In asymptomatic patients with mitral stenosis, surgery is limited
to those rare patients at high risk of cardiac complications who
have contraindications for PMC and are at low risk for surgery.
The most important contraindication to PMC is LA thrombus
(Table 8). However, when the thrombus is located in the LA ap-
pendage, PMC may be considered in patients without urgent
need for intervention, provided repeat TOE shows the thrombus
has disappeared after 1–3 months of oral anticoagulation.
Surgery is indicated if the thrombus persists.
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7.3 Medical therapy
Diuretics, beta-blockers, digoxin or heart rate–regulating calcium
channel blockers can transiently improve symptoms.
Anticoagulation with a target international normalized ratio (INR)
between 2 and 3 is indicated in patients with either new-onset or
paroxysmal atrial fibrillation.
In patients in sinus rhythm, oral anticoagulation is indicated
when there has been a history of systemic embolism or a throm-
bus is present in the LA (recommendation class I, level of evi-
dence C) and should also be considered when TOE shows dense
spontaneous echocardiographic contrast or an enlarged LA (M-
mode diameter >50 mm or LA volume >60 ml/m2) (recommen-
dation class IIa, level of evidence C). Patients with moderate to
severe mitral stenosis and persistent atrial fibrillation should be
kept on vitamin K antagonist (VKA) treatment and not receive
NOACs.
Cardioversion is not indicated before intervention in patients
with severe mitral stenosis, as it does not durably restore sinus
rhythm. If atrial fibrillation is of recent onset and the LA is only
moderately enlarged, cardioversion should be performed soon
after successful intervention.
7.4 Serial testing
Asymptomatic patients with clinically significant mitral stenosis
who have not undergone intervention should be followed up
yearly by means of clinical and echocardiographic examin-
ations and at longer intervals (2–3 years) in case of moderate
stenosis.
Management of patients after successful PMC is similar to that
of asymptomatic patients. Follow-up should be more frequent if
asymptomatic restenosis occurs. When PMC is not successful,
surgery should be considered early unless there are definite
contraindications.
7.5 Special patient populations
When restenosis with symptoms occurs after surgical commissur-
otomy or PMC, reintervention in most cases requires valve re-
placement, but PMC can be proposed in selected candidates
with favourable characteristics if the predominant mechanism is
commissural refusion [151].
In the elderly population with rheumatic mitral stenosis
when surgery is high risk, PMC is a useful option, even if only
palliative. In other elderly patients, surgery is preferable
[146,148,149]. However, in elderly patients with degenerative
mitral stenosis with severely calcified mitral annulus, surgery is
very high risk. As there is no commissural fusion in these cases,
degenerative mitral stenosis is not amenable to PMC [143].
If degenerative mitral stenosis is severe, very preliminary experi-
ence has suggested that transcatheter valve implantation of
a TAVI bioprosthesis in the mitral position is feasible in symp-
tomatic elderly patients who are inoperable if the anatomy is
suitable [152].
In patients with severe mitral stenosis combined with severe
aortic valve disease, surgery is preferable when it is not contrain-
dicated. The management of patients in whom surgery is contra-
indicated is difficult and requires a comprehensive and
individualized evaluation by the Heart Team.
In cases with severe mitral stenosis with moderate aortic valve
disease, PMC can be performed to postpone the surgical treat-
ment of both valves.
In patients with severe tricuspid regurgitation, PMC may be
considered in selected patients with sinus rhythm, moderate
atrial enlargement and functional tricuspid regurgitation second-
ary to pulmonary hypertension. In other cases, surgery on both
valves is preferred [153].
Valve replacement is the only option for the treatment of rare
cases of severe mitral stenosis of non-rheumatic origin where
commissural fusion is absent.
Key points
• Most patients with severe mitral stenosis and favourable valve
anatomy currently undergo PMC.
Indications for PMC and mitral valve surgery in clini-
cally significant (moderate or severe) mitral stenosis
(valve area1.5 cm2)
Recommendations Classa Levelb
PMC is indicated in symptomatic patients
without unfavourable characteristicsc for
PMC [144, 146, 148].
I B
PMC is indicated in any symptomatic
patients with a contraindication or a high
risk for surgery.
I C
Mitral valve surgery is indicated in sympto-
matic patients who are not suitable for
PMC.
I C
PMC should be considered as initial treat-
ment in symptomatic patients with subop-
timal anatomy but no unfavourable clinical
characteristics for PMC.c
IIa C
PMC should be considered in asympto-
matic patients without unfavourable clini-
cal and anatomical characteristicsc for
PMC and:
• high thromboembolic risk (history of
systemic embolism, dense spontaneous
contrast in the LA, new-onset or parox-
ysmal atrial fibrillation), and/or
• high risk of haemodynamic decompen-
sation (systolic pulmonary pressure
>50 mmHg at rest, need for major non-
cardiac surgery, desire for pregnancy).
IIa C
LA: left atrium; PMC: percutaneous mitral commissurotomy.
aClass of recommendation.
bLevel of evidence.
cUnfavourable characteristics for PMC can be defined by the presence
of several of the following characteristics. Clinical characteristics: old
age, history of commissurotomy, New York Heart Association class IV,
permanent atrial fibrillation, severe pulmonary hypertension.
Anatomical characteristics: echocardiographic score >8, Cormier score
3 (calcification of mitral valve of any extent as assessed by fluoroscopy),
very small mitral valve area, severe tricuspid regurgitation. For the defi-
nition of scores see Table 9.
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• Decision making as to the type of intervention in patients
with unfavourable anatomy is still a matter of debate and
must take into account the multifactorial nature of predicting
the results of PMC.
Gaps in evidence
• The scores predicting the results and complications of PMC,
particularly those of severe mitral regurgitation, must be
refined.
• The potential role of transcatheter mitral valve implantation in
high-risk patients is to be determined, particularly those with
severe degenerative mitral stenosis.
8. TRICUSPID REGURGITATION
Pathological tricuspid regurgitation is more often secondary, due
to RV dysfunction following pressure and/or volume overload in
the presence of structurally normal leaflets [2]. Possible causes of
primary tricuspid regurgitation are infective endocarditis
Figure 5: Management of clinically significant mitral stenosis. CI: contraindication; MS: mitral stenosis; PMC: percutaneous mitral commissurotomy.
aHigh thromboembolic risk: history of systemic embolism, dense spontaneous contrast in the left atrium, new-onset atrial fibrillation. High-risk of haemo-
dynamic decompensation: systolic pulmonary pressure >50 mmHg at rest, need for major non-cardiac surgery, desire for pregnancy. bSurgical commissurot-
omy may be considered by experienced surgical teams or in patients with contraindications to PMC. cSee table of recommendations on indications for PMC
and mitral valve surgery in clinically significant mitral stenosis in section 7.2. dSurgery if symptoms occur for a low level of exercise and operative risk is low.
Table 8: Contraindications for percutaneous mitral com-
missurotomy (PMC)a
CAD: coronary artery disease.
aPMC may be considered in patients with valve area >1.5 cm2 with
symptoms that cannot be explained by another cause and if the anat-
omy is favourable.
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(especially in intravenous drug addicts) [154], rheumatic heart
disease, carcinoid syndrome, myxomatous disease, endomyocar-
dial fibrosis, Ebstein’s anomaly and congenitally dysplastic valves,
drug-induced valve diseases, thoracic trauma and iatrogenic
valve damage.
8.1. Evaluation
Echocardiography is the ideal technique to evaluate tricuspid
regurgitation. In primary tricuspid regurgitation, the aetiology
can usually be identified from specific abnormalities of the valve
structure [28, 115]. In secondary tricuspid regurgitation, the de-
gree of dilatation of the annulus, the RV dimension and function
and the degree of tricuspid valve deformation should be meas-
ured [2]. Evaluation of tricuspid regurgitation severity (integra-
tion of multiple qualitative and quantitative parameters) and
pulmonary systolic pressure should be carried out as currently
recommended (Table 4) [2]. It has to be noted that the problem
of elevated pulmonary vascular resistance may be disguised in
the presence of severe tricuspid regurgitation since its velocity
may be lower than expected in the case of pulmonary
hypertension.
Evaluations of RV dimensions and function should be con-
ducted despite the existing limitations of current indices of RV
function [53]. The presence of associated lesions (looking care-
fully at the associated valve lesions, particularly on the left side)
and LV function should be assessed.
In experienced laboratories, 3D measurements of RV vol-
umes can be considered, which may be similar to those ob-
tained by CMR [155]. However, when available, CMR is the
preferred method for evaluating RV size and function and rep-
resents the gold standard for assessing RV volumes and func-
tion [155].
Cardiac catheterization is not needed to diagnose tricuspid re-
gurgitation or estimate its severity but should be obtained in pa-
tients in whom isolated tricuspid valve surgery is contemplated
for secondary tricuspid regurgitation to evaluate haemo-
dynamics, in particular pulmonary vascular resistance.
Table 9: Echo scores: Wilkins score [145], Cormier score [150], and Echo Score “Revisited” for immediate outcome prediction [146]
score [145]
score [150]
prediction [146]
Risk groups for Echo score “Revisited”: low (score 0 - 3); intermediate (score 4 - 5); high (score 6 - 11).
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8.2. Indications for intervention
The timing of surgical intervention remains controversial, mostly
due to the limited data available and their heterogeneous nature
(see table of recommendations for indications for tricuspid valve
surgery and Figure 6) [156–160]. Surgery should be carried out
sufficiently early to avoid irreversible RV dysfunction.
In severe primary tricuspid regurgitation, surgery is not only
recommended in symptomatic patients but should also be con-
sidered in asymptomatic patients when progressive RV dilatation
or decline of RV function is observed. Although these patients re-
spond well to diuretic therapy, delaying surgery is likely to result
in irreversible RV damage, organ failure and poor results of late
surgical intervention.
In secondary tricuspid regurgitation, adding a tricuspid re-
pair, if indicated, during left-sided surgery does not increase op-
erative risk and has been demonstrated to provide reverse
remodelling of the RV and improvement of functional status
even in the absence of substantial tricuspid regurgitation when
annulus dilatation is present [156, 157, 160]. It should therefore
be performed liberally. Reoperation on the tricuspid valve in
cases of persistent tricuspid regurgitation after mitral valve sur-
gery carries a high risk, mostly due to the late referral and the
consequently poor clinical condition of patients. To improve
the prognosis of patients in this challenging scenario, the treat-
ment of severe late tricuspid regurgitation following left-sided
valve surgery should be considered earlier, even in asymptom-
atic patients, if there are signs of progressive RV dilatation or
decline in RV function and in the absence of left-sided valve
dysfunction, severe RV or LV dysfunction and severe pulmonary
vascular disease/hypertension.
If possible, valve repair is preferable to valve replacement. Ring
annuloplasty, preferably with prosthetic rings, is key to surgery for
secondary tricuspid regurgitation [156, 161]. Valve replacement
should be considered when the tricuspid valve leaflets are signifi-
cantly tethered and the annulus is severely dilated. In the presence
of transtricuspid pacemaker leads, the technique used should be
adapted to the patient’s condition and the surgeon’s experience.
Percutaneous repair techniques are in their infancy and must be
further evaluated before any recommendations can be made.
Figure 6: Indications for surgery in tricuspid regurgitation. LV: left ventricular; RV: right ventricular; TA: tricuspid annulus; TR: tricuspid regurgitation; TV: tricuspid
valve; TVR: tricuspid valve replacement.
aTA >_ 40 mm or > 21 mm/m2.
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9. TRICUSPID STENOSIS
Tricuspid stenosis is often combined with tricuspid regurgitation,
most frequently of rheumatic origin. It is therefore almost always
associated with left-sided valve lesions, particularly mitral sten-
osis, that usually dominate the clinical presentation. Other causes
are rare, including congenital, drug-induced valve diseases,
Whipple’s disease, endocarditis and large right atrial tumour.
9.1 Evaluation
Echocardiography provides the most useful information.
Tricuspid stenosis is often overlooked and requires careful evalu-
ation. Echocardiographic evaluation of the anatomy of the valve
and its subvalvular apparatus is important to assess valve repar-
ability. No generally accepted grading of tricuspid stenosis sever-
ity exists, but a mean gradient >_5 mmHg at normal heart rate is
considered indicative of clinically significant tricuspid stenosis [3].
Catheterization is no longer used for evaluating the severity of
tricuspid stenosis.
9.2 Indications for intervention
The lack of pliable leaflet tissue is the main limitation for valve re-
pair. Even though this is still a matter of debate, biological pros-
theses for valve replacement are usually preferred over
mechanical ones because of the high risk of thrombosis carried
by the latter and the satisfactory long-term durability of the for-
mer in the tricuspid position [162].
Percutaneous balloon tricuspid dilatation has been performed
in a limited number of cases, either alone or alongside PMC, but
frequently induces significant regurgitation. There is a lack of
data on long-term results [163].
Intervention on the tricuspid valve is usually carried out at the
time of intervention on the other valves in patients who are
symptomatic despite medical therapy. The choice between repair
or valve replacement depends on valve anatomy and surgical ex-
pertise. Balloon commissurotomy can be considered in the rare
cases with anatomically suitable valves when tricuspid stenosis is
isolated, or additional mitral stenosis can also be treated inter-
ventionally (see table of recommendations in section 7.2 listing
indications for PMC and mitral valve surgery in clinically signifi-
cant mitral stenosis).
9.3 Medical therapy
Diuretics are useful in the presence of heart failure but are of lim-
ited long-term efficacy.
Key points
• Tricuspid stenosis is a rare condition, whereas tricuspid regur-
gitation is more common, especially in its secondary form.
• For appropriate management, secondary tricuspid regurgita-
tion has to be clearly distinguished from primary tricuspid
regurgitation.
Indications for tricuspid valve surgery
Recommendations Classa Levelb
Recommendations on tricuspid stenosis
Surgery is indicated in symptomatic
patients with severe tricuspid stenosis.c
I C
Surgery is indicated in patients with severe
tricuspid stenosis undergoing left-sided
valve intervention.d
I C
Recommendations on primary tricuspid regurgitation
Surgery is indicated in patients with severe
primary tricuspid regurgitation undergoing
left-sided valve surgery.
I C
Surgery is indicated in symptomatic
patients with severe isolated primary tri-
cuspid regurgitation without severe RV
dysfunction.
I C
Surgery should be considered in patients
with moderate primary tricuspid regurgita-
tion undergoing left-sided valve surgery.
IIa C
Surgery should be considered in asympto-
matic or mildly symptomatic patients with
severe isolated primary tricuspid regurgita-
tion and progressive RV dilatation or dete-
rioration of RV function.
IIa C
Recommendations on secondary tricuspid regurgitation
Surgery is indicated in patients with severe
secondary tricuspid regurgitation under-
going left-sided valve surgery.
I C
Surgery should be considered in patients
with mild or moderate secondary tricuspid
regurgitation with a dilated annulus
(>_40 mm or >21 mm/m2 by 2D echocar-
diography) undergoing left-sided valve
surgery.
IIa C
Surgery may be considered in patients
undergoing left-sided valve surgery with
mild or moderate secondary tricuspid
regurgitation even in the absence of annu-
lar dilatation when previous recent right-
heart failure has been documented.
IIb C
After previous left-sided surgery and in
absence of recurrent left-sided valve dysfunc-
tion, surgery should be considered in patients
with severe tricuspid regurgitation who are
symptomatic or have progressive RV dilata-
tion/dysfunction, in the absence of severe RV
or LV dysfunction and severe pulmonary vas-
cular disease/hypertension.
IIa C
2D: two-dimensional; LV: left ventricular; PMC: percutaneous mitral
commissurotomy; RV: right ventricular.
aClass of recommendation.
bLevel of evidence.
cPercutaneous balloon valvuloplasty can be attempted as a first
approach if tricuspid stenosis is isolated.
dPercutaneous balloon valvuloplasty can be attempted if PMC can be
performed on the mitral valve.
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• Similar to mitral regurgitation, primary tricuspid regurgitation
requires intervention sufficiently early to avoid secondary
damage of the RV, which is associated with poor outcome.
• Secondary tricuspid regurgitation should be liberally treated
at the time of left-sided valve surgery.
• Consideration of isolated surgery of secondary tricuspid re-
gurgitation after previous left-sided valve surgery requires
comprehensive assessment of the underlying disease, pul-
monary haemodynamics and RV function.
Gaps in evidence
• Criteria for optimal timing of surgery in primary tricuspid re-
gurgitation require refinement.
• Criteria for concomitant tricuspid valve surgery at the time of
left-sided surgery in patients without severe tricuspid valve
disease require refinement.
• The potential role of transcatheter tricuspid valve treatment in
high-risk patients needs to be determined.
10. COMBINED AND MULTIPLE-VALVE DISEASES
Significant stenosis and regurgitation can be found on the same
valve. Disease of multiple valves may be encountered in several
conditions, particularly in rheumatic and congenital heart dis-
ease, but also less frequently in degenerative valve disease. There
is a lack of data on combined or multiple-valve diseases. This
does not allow for evidence-based recommendations [164]. The
general principles for the management of combined or multiple-
valve disease are as follows:
• When either stenosis or regurgitation is predominant, man-
agement follows the recommendations concerning the pre-
dominant VHD. When the severity of both stenosis and
regurgitation is balanced, indications for interventions should
be based on symptoms and objective consequences rather
than on the indices of severity of stenosis or regurgitation. In
this setting, consideration of the pressure gradient that reflects
the haemodynamic burden of the valve lesion becomes more
important than valve area and measures of the regurgitation
for the assessment of disease severity.
• Besides the separate assessment of each valve lesion, it is ne-
cessary to take into account the interaction between the dif-
ferent valve lesions. As an illustration, associated mitral
regurgitation may lead to underestimation of the severity of
aortic stenosis, as decreased stroke volume due to mitral re-
gurgitation lowers the flow across the aortic valve and hence
the aortic gradient. This underlines the need to combine dif-
ferent measurements, including assessment of valve areas, if
possible using methods that are less dependent on loading
conditions, such as planimetry.
• Indications for intervention are based on global assessment of
the consequences of the different valve lesions (i.e. symptoms
or presence of LV dilatation or dysfunction). Intervention can
be considered for non-severe multiple lesions associated with
symptoms or leading to LV impairment.
• The decision to intervene on multiple valves should take into
account the extra surgical risk of combined procedures.
• The choice of surgical technique should take into account
the presence of the other VHD; repair remains the ideal
option.
The management of specific associations of VHD is detailed in
the individual sections of this document.
Key points
• In combined VHD, pathology is considered severe even if
both stenosis and regurgitation are only of moderate severity
and pressure gradients become of major importance for
assessment.
• Management of multiple valve disease is dictated by the pre-
dominant VHD.
Gaps in evidence
• More data on the natural history and the impact of interven-
tion on outcome are required to better define the indications
for intervention.
11. PROSTHETIC VALVES
Every valve prosthesis introduces a new disease process. In prac-
tice, the choice is between a mechanical and a biological pros-
thesis. Randomized trials comparing both prostheses consistently
found similar survival, no significant difference in rates of valve
thrombosis and thromboembolism, higher rates of bleeding with
mechanical prostheses and higher rates of reintervention with
bioprostheses [165–167].
11.1 Choice of prosthetic valve
The choice between a mechanical and a biological valve in adults
is determined mainly by estimating the risk of anticoagulation-
related bleeding and thromboembolism with a mechanical valve
versus the risk of structural valve deterioration with a bioprosthe-
sis and by considering the patient’s lifestyle and preferences.
Rather than setting arbitrary age limits, prosthesis choice should
be discussed in detail with the informed patient, cardiologists
and surgeons, taking into account the factors detailed below (see
tables of recommendations in section 11.1). Bioprostheses should
be considered in patients whose life expectancy is lower than the
presumed durability of the bioprosthesis, particularly if comor-
bidities may necessitate further surgical procedures, and in those
with increased bleeding risk. In women who wish to become
pregnant, the high risk of thromboembolic complications with a
mechanical prosthesis during pregnancy and the low risk of
elective reoperation are incentives to consider a bioprosthesis,
despite the rapid occurrence of structural valve deterioration in
this age group.
11.2 Management after valve intervention
Thromboembolism and anticoagulant-related bleeding present
the majority of complications experienced by prosthetic valve re-
cipients. Endocarditis prophylaxis and management of prosthetic
valve endocarditis are detailed in a separate ESC guideline [28].
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11.2.1 Baseline assessment and modalities of follow-up.
All patients require lifelong follow-up by a cardiologist after valve
surgery to detect early deterioration in prosthetic function or
ventricular function or progressive disease of another heart valve.
Clinical assessment should be performed yearly or as soon as
possible if new cardiac symptoms occur. TTE should be per-
formed if any new symptoms occur after valve replacement or if
complications are suspected. After transcatheter as well as surgi-
cal implantation of a bioprosthetic valve, echocardiography,
including the measurement of transprosthetic gradients, should
be performed within 30 days (preferably 30 days for surgery)
after valve implantation (i.e. baseline imaging), at 1 year after im-
plantation and annually thereafter [168]. TOE should be con-
sidered if TTE is of poor quality and in all cases of suspected
prosthetic dysfunction or endocarditis [169,170]. Cinefluoroscopy
for mechanical valves and MSCT scanning provide useful add-
itional information if valve thrombus or pannus are suspected to
impair valve function [170].
11.2.2 Antithrombotic management.
11.2.2.1 General management. Antithrombotic management should
address effective control of modifiable risk factors for thrombo-
embolism in addition to the prescription of antithrombotic drugs
[171]. Indications for antithrombotic therapy after valve repair or
replacement are summarized in the table of recommendations
for indications for antithrombotic therapy after valvular surgery.
In patients with surgical aortic bioprostheses, the use of low-
dose aspirin is now favoured as an alternative to postoperative
anticoagulant therapy, although this relies on low-level evidence
[42, 172, 173].
When postoperative anticoagulant therapy is indicated, oral anti-
coagulation should be started during the first postoperative days.
Intravenous unfractionated heparin (UFH), monitored to an acti-
vated partial thromboplastin time of 1.5–2.0 times the control
value, enables rapid anticoagulation to be obtained before the INR
Choice of the aortic/mitral prosthesis in favour of a bio-
prosthesis; the decision is based on the integration of
several of the following factors
Recommendations Classa Levelb
A bioprosthesis is recommended accord-
ing to the desire of the informed patient.
I C
A bioprosthesis is recommended when
good-quality anticoagulation is unlikely
(compliance problems, not readily avail-
able) or contraindicated because of high
bleeding risk (previous major bleed,
comorbidities, unwillingness, compliance
problems, lifestyle, occupation).
I C
A bioprosthesis is recommended for reop-
eration for mechanical valve thrombosis
despite good long-term anticoagulant
control.
I C
A bioprosthesis should be considered in
patients for whom there is a low likelihood
and/or a low operative risk of future redo
valve surgery.
IIa C
A bioprosthesis should be considered in
young women contemplating pregnancy.
IIa C
A bioprosthesis should be considered in
patients >65 years of age for a prosthesis in
the aortic position or >70 years of age in a
mitral position or those with a life expect-
ancyc lower than the presumed durability
of the bioprosthesis.d
IIa C
aClass of recommendation.
bLevel of evidence.
cLife expectancy should be estimated according to age, sex, comorbid-
ities and country-specific life expectancy.
dIn patients 60–65 years of age who should receive an aortic prosthesis
and those between 65 and 70 years of age in the case of mitral prosthe-
sis, both valves are acceptable and the choice requires careful analysis
of factors other than age.
Choice of the aortic/mitral prosthesis in favour of a
mechanical prosthesis; the decision is based on the inte-
gration of several of the following factors
Recommendations Classa Levelb
A mechanical prosthesis is recommended
according to the desire of the informed
patient and if there are no contraindica-
tions to long-term anticoagulation.c
I C
A mechanical prosthesis is recommended
in patients at risk of accelerated structural
valve deterioration.d
I C
A mechanical prosthesis should be consid-
ered in patients already on anticoagulation
because of a mechanical prosthesis in
another valve position.
IIa C
A mechanical prosthesis should be consid-
ered in patients <60 years of age for pros-
theses in the aortic position and <65 years
of age for prostheses in the mitral
position.e
IIa C
A mechanical prosthesis should be consid-
ered in patients with a reasonable life
expectancyf for whom future redo valve
surgery would be at high risk.
IIa C
A mechanical prosthesis may be considered
in patients already on long-term anticoagu-
lation due to the high risk for
thromboembolism.g
IIb C
LV: left ventricular.
aClass of recommendation.
bLevel of evidence.
cIncreased bleeding risk because of comorbidities, compliance con-
cerns or geographic, lifestyle or occupational conditions.
dYoung age (<40 years), hyperparathyroidism.
eIn patients 60–65 years of age who should receive an aortic prosthesis
and those between 65 and 70 years of age in the case of mitral prosthe-
sis, both valves are acceptable and the choice requires careful analysis
of factors other than age.
fLife expectancy should be estimated at >10 years according to age, sex,
comorbidities and country-specific life expectancy.
gRisk factors for thromboembolism are atrial fibrillation, previous
thromboembolism, hypercoagulable state and severe LV systolic
dysfunction.
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rises [42]. Low-molecular-weight heparin (LMWH) seems to offer ef-
fective and stable anticoagulation and has been used in observa-
tional series mostly using enoxaparin [174, 175]. This is off-label use.
The first postoperative month is a high-risk period for
thromboembolism. The addition of aspirin to anticoagulant ther-
apy decreases postoperative thromboembolic risk but increases
bleeding risk and cannot be recommended routinely [176].
VKAs should be favoured when long-term anticoagulant ther-
apy is needed in patients with a bioprosthesis. Despite the ab-
sence of data from clinical trials, NOACs can be used in patients
who have atrial fibrillation associated with a bioprosthesis after
the third postoperative month [43]. There is no evidence to sup-
port the use of antiplatelet agents beyond 3 months in patients
with surgical bioprostheses who do not have an indication other
than the presence of the bioprosthesis itself.
A combination of low-dose aspirin and a thienopyridine is com-
monly used early after TAVI, followed by aspirin or a thienopyri-
dine alone in patients who have no other indication for oral
anticoagulation. Recent data suggest that single antiplatelet ther-
apy may have a better safety profile than dual antiplatelet therapy
after TAVI [177]. Observational findings suggest that anticoagulant
therapy reduces the incidence of subclinical thrombosis compared
with dual antiplatelet therapy [178]. The results of ongoing large-
scale, dedicated trials are needed to improve evidence in this field.
11.2.2.2 Target international normalized ratio. Target INR should be
adapted to patient risk factors and the thrombogenicity of the pros-
thesis (Table 10) [171]. Recent randomized trials supported lower
target INRs for aortic prostheses [186–188]. However, limited statis-
tical power, certain methodological concerns and the restriction to
certain prostheses and/or to the use of INR self-management led
the Task Force not to change recommendations for target INR.
We recommend a median INR value rather than a range to
avoid considering extreme values in the target range as a valid tar-
get INR. High variability of the INR is a strong independent pre-
dictor of reduced survival after valve replacement. There is now
evidence that INR self-management reduces INR variability and
clinical events, including patients with heart valve prosthesis [181];
however, appropriate training and regular quality control are
required. However, monitoring by an anticoagulant clinic should
be considered for patients with unstable INR or anticoagulant-
related complications. Systematic genotyping of patients on VKA
treatment is not recommended in the absence of convincing clin-
ical benefit and concerns regarding cost-effectiveness [189].
11.2.2.3 Management of vitamin K antagonist overdose and bleed-
ing. The risk of major bleeding rises considerably when the INR
exceeds 4.5 and increases exponentially above an INR of 6.0. An
INR >_6.0 therefore requires rapid reversal of anticoagulation be-
cause of the risk of subsequent bleeding.
In the absence of bleeding, management depends on the target
INR, the actual INR and the half-life of the VKA used. It is possible
to stop oral anticoagulation and to allow the INR to fall gradually
or to give oral vitamin K in increments of 1 or 2 mg [190].
Immediate reversal of anticoagulation using intravenous prothrom-
bin complex concentrate and vitamin K is required only for severe
bleeding, defined as not amenable to local control, threatening life
or important organ function (e.g. intracranial bleeding), causing
haemodynamic instability or requiring an emergency surgical pro-
cedure or transfusion [190]. There are no data suggesting that the
risk of thromboembolism due to transient reversal of anticoagula-
tion outweighs the consequences of severe bleeding in patients
with mechanical prostheses. The optimal time to restart anticoagu-
lant therapy should be discussed in relation to the location of the
bleeding event, its evolution and interventions performed to stop
bleeding and/or to treat an underlying cause [191].
11.2.2.4 Combination of oral anticoagulants with antiplatelet drugs.
The addition of aspirin with contemporary target INRs has not
been studied in patients without vascular disease [42]. Underlying
uncertainties on the risk–benefit ratio of the combination of VKA
with aspirin account for discrepancies between different recom-
mendations [192, 193]. When added to anticoagulation, antipla-
telet agents decrease thromboembolic risk but increase the risk
of major bleeding [194]. Therefore they should not be prescribed
to all patients with prosthetic valves but should be reserved for
specific indications according to the analysis of benefit and
increased risk of major bleeding. If used, the lower recom-
mended dose should be prescribed (e.g. aspirin 75–100 mg/day).
Indications for the addition of an antiplatelet agent to oral anti-
coagulants are detailed in section 11.2.2.1 (see table of recommen-
dations for indications for antithrombotic therapy in patients with
a prosthetic heart valve or valve repair) and in Figure 7. The use of
prasugrel or ticagrelor as part of triple therapy should be avoided
[37]. During triple antithrombotic therapy, close monitoring of INR
is advised and INR should be kept in the low target range.
11.2.2.5 Interruption of anticoagulant therapy for planned invasive
procedures. Anticoagulation during non-cardiac surgery requires
careful management based on risk assessment [196]. It is recom-
mended not to interrupt oral anticoagulation for most minor surgi-
cal procedures (including dental extraction, cataract removal) and
those procedures where bleeding is easily controlled [197]. Major
surgical procedures require an INR <1.5. In patients with a mechan-
ical prosthesis, oral anticoagulant therapy should be stopped before
surgery and bridging using heparin is recommended [196]. UFH re-
mains the only approved heparin treatment in patients with mech-
anical prostheses; intravenous administration should be favoured
over the subcutaneous route. The use of subcutaneous LMWH, al-
though off-label, is an alternative to UFH for bridging. When
LMWHs are used they should be administered twice a day using
Table 10: Target INR for mechanical prostheses
INR: international normalized ratio; LVEF: left ventricular ejection
fraction.
aMitral or tricuspid valve replacement; previous thromboembolism;
atrial fibrillation; mitral stenosis of any degree; LVEF <35%.
bCarbomedics, Medtronic Hall, ATS, Medtronic Open-Pivot, St Jude
Medical, On-X, Sorin Bicarbon.
cOther bileaflet valves with insufficient data.
dLillehei-Kaster, Omniscience, Starr-Edwards (ball-cage), Bjork-Shiley
and other tilting-disc valves.
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Indications for antithrombotic therapy in patients with a prosthetic heart valve or valve repair
Recommendations Classa Levelb
Mechanical prostheses
Oral anticoagulation using a VKA is recommended lifelong for all patients [179, 180]. I B
Bridging using therapeutic doses of UFH or LMWH is recommended when VKA treatment should be
interrupted.
I C
The addition of low-dose aspirin (75–100 mg/day) to VKA should be considered after thromboembolism
despite an adequate INR.
IIa C
The addition of low-dose aspirin (75–100 mg/day) to VKA may be considered in the case of concomitant
atherosclerotic disease.
IIb C
INR self-management is recommended provided appropriate training and quality control are performed [181]. I B
In patients treated with coronary stent implantation, triple therapy with aspirin (75–100 mg/day), clopidog-
rel (75 mg/day) and VKA should be considered for 1 month, irrespective of the type of stent used and the
clinical presentation (i.e. ACS or stable CAD) [182].
IIa B
Triple therapy comprising aspirin (75–100 mg/day), clopidogrel (75 mg/day) and VKA for >1 month and up to
6 months should be considered in patients with high ischaemic risk due to ACS or other anatomical/procedural
characteristics that outweighs the bleeding risk [182].
IIa B
Dual therapy comprising VKA and clopidogrel (75 mg/day) should be considered as an alternative to 1-
month triple antithrombotic therapy in patients in whom the bleeding risk outweighs the ischaemic risk
[183, 184].
IIa A
In patients who have undergone PCI, discontinuation of antiplatelet treatment should be
considered at 12 months [185].
IIa B
In patients requiring aspirin and/or clopidogrel in addition to VKA, the dose intensity of VKA should be
carefully regulated with a target INR in the lower part of the recommended target range and a time in the
therapeutic range >65–70% [182, 184].
IIa B
The use of NOACs is contraindicated [45]. III B
Bioprostheses
Oral anticoagulation is recommended lifelong for patients with surgical or transcatheter implanted biopros-
theses who have other indications for anticoagulation.c
I C
Oral anticoagulation using a VKA should be considered for the first 3 months after surgical implantation of a
mitral or tricuspid bioprosthesis.
IIa C
Oral anticoagulation using a VKA should be considered for the first 3 months after surgical mitral or tricus-
pid valve repair.
IIa C
Low-dose aspirin (75–100 mg/day) should be considered for the first 3 months after surgical implantation of
an aortic bioprosthesis or valve-sparing aortic surgery.
IIa C
Dual antiplatelet therapy should be considered for the first 3–6 months after TAVI, followed by lifelong sin-
gle antiplatelet therapy in patients who do not need oral anticoagulation for other reasons.
IIa C
Single antiplatelet therapy may be considered after TAVI in the case of high bleeding risk. IIb C
Oral anticoagulation may be considered for the first 3 months after surgical implantation of an aortic
bioprosthesis.
IIb C
ACS: acute coronary syndrome; CAD: coronary artery disease; INR: international normalized ratio; LMWH: low-molecular-weight heparin; LV: left ventricular; PCI: per-
cutaneous coronary intervention; NOAC: non-vitamin K antagonist oral anticoagulant; TAVI: transcatheter aortic valve implantation; UFH: unfractionated heparin; VKA:
vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
cAtrial fibrillation, venous thromboembolism, hypercoagulable state or, with a lesser degree of evidence, severely impaired LV dysfunction (ejection fraction
<35%).
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therapeutic doses, adapted to body weight and renal function and,
if possible, with monitoring of anti-Xa activity with a target of 0.5–
1.0 U/ml. Fondaparinux should not be used for bridging in patients
with mechanical prosthesis. Practical modalities of anticoagulation
bridging are detailed in Figure 8.
If required, after a careful risk–benefit assessment, combined
aspirin therapy should be discontinued 1 week before a non-
cardiac procedure.
Oral anticoagulation can be continued at modified doses in
the majority of patients who undergo cardiac catheterization, in
particular using the radial approach. In patients who require
transseptal catheterization for valvular interventions, direct LV
puncture or pericardial drainage, oral anticoagulants should be
stopped and bridging anticoagulation administered [171].
In patients who have a subtherapeutic INR during routine
monitoring, bridging with UFH or preferably LMWH in an outpa-
tient setting is indicated until a therapeutic INR value is reached.
11.2.3 Management of valve thrombosis. Obstructive valve
thrombosis should be suspected promptly in any patient with
any type of prosthetic valve who presents with recent dyspnoea
or an embolic event. The diagnosis should be confirmed by TTE
and TOE, cinefluoroscopy or CT scan if promptly available [169,
170].
The management of mechanical prosthetic valve thrombosis is
high risk, whatever the option taken. Surgery is high risk because
it is most often performed under emergency conditions and is a
reintervention. On the other hand, fibrinolysis carries risks of
bleeding, systemic embolism and recurrent thrombosis that are
higher than after surgery [198].
Emergency valve replacement is recommended for obstructive
prosthetic valve thrombosis in critically ill patients without a
contraindication to surgery (see table of recommendations in
section 11.2.3 for management of prosthetic dysfunction and
Figure 9).
Figure 7: Antithrombotic therapy in patients with mechanical valve prosthesis undergoing PCI (adapted from the 2017 ESC Focused Update on Dual Antiplatelet
Therapy [195]). A: aspirin; ABC: age, biomarkers, clinical history; ACS: acute coronary syndrome; C: clopidogrel; mo.: month(s); O: oral anticoagulation with a vitamin K
antagonist; PCI: percutaneous coronary intervention. For more details regarding estimation of bleeding risk (HAS-BLED and ABC score) see the 2017 ESC Focused
Update on Dual Antiplatelet Therapy [195].
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Management of non-obstructive mechanical prosthetic valve
thrombosis depends mainly on the occurrence of a thrombo-
embolic event and the size of the thrombus (Figure 10). Surgery
should be considered for a large (>10 mm) non-obstructive pros-
thetic valve thrombus complicated by embolism or which per-
sists despite optimal anticoagulation [199]. Fibrinolysis may be
considered if surgery is at high risk but carries a risk of bleeding
and thromboembolism.
Valve thrombosis occurs mainly in mechanical prostheses.
However, cases of thrombosis of bioprostheses have been re-
ported after surgery or transcatheter valve implantation [200,201].
Subclinical thrombosis of bioprostheses may be more frequent
when assessed by cardiac CT [202], and subclinical thrombosis of
TAVI prostheses can be associated with a moderate increase in
transprosthetic gradients, but the clinical consequences are un-
known [203].
Figure 8: Main bridging steps for an intervention requiring interruption of oral anticoagulation in a patient with a mechanical prosthesis. Timing should be individual-
ized according to patient characteristics, actual INR, and the type of intervention (reproduced with permission from Iung and Rodes-Cabau [42]). INR: international
normalized ratio; IV: intravenous; LMWH: low-molecular-weight heparin; UFH: unfractionated heparin; VKA: vitamin K antagonist.
aIV UFH may be favoured in patients at high thrombotic risk.
Figure 9: Management of left-sided obstructive mechanical prosthetic thrombosis. IV: intravenous; TOE: transoesophageal echocardiography; TTE: transthoracic
echocardiography; UFH: unfractionated heparin.
aRisk and benefits of both treatments should be individualized. The presence of a first-generation prosthesis is an incentive to surgery.
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Anticoagulation using a VKA and/or UFH is the first-line treat-
ment of bioprosthetic valve thrombosis.
11.2.4 Management of thromboembolism. Thromboembolism
after valve surgery is multifactorial in origin [171]. Thorough inves-
tigation of each episode of thromboembolism is therefore
essential (including cardiac and non-cardiac imaging) (Figure 10)
rather than simply increasing the target INR or adding an antipla-
telet agent. Prevention of further thromboembolic events involves
the treatment of risk factors, optimization of anticoagulation con-
trol and the addition of low-dose aspirin (<_100 mg daily) after
careful analysis of the risk–benefit ratio.
11.2.5 Management of haemolysis and paravalvular
leak. Blood tests for haemolysis should be part of routine follow-
up after valve replacement. Lactate dehydrogenase, although non-
specific, is related to the severity of haemolysis. The diagnosis of
haemolytic anaemia requires TOE to detect a paravalvular leak if
TTE is not contributory. Reoperation is recommended if the para-
valvular leak is related to endocarditis or causes haemolysis requir-
ing repeated blood transfusions or leading to severe symptoms
(see table of recommendations in section 11.2.3 for management
of prosthetic dysfunction). Medical therapy, including iron supple-
mentation, beta-blockers and erythropoietin, is indicated in pa-
tients with severe haemolytic anaemia when contraindications to
surgery are present. Transcatheter closure of a paravalvular leak is
feasible, but experience is limited and there is presently no conclu-
sive evidence to show a consistent efficiency [204].
11.2.6 Management of bioprosthetic valve failure. After
transcatheter as well as surgical implantation of a bioprosthetic
valve, echocardiography including the measurement of transpros-
thetic gradients should be performed within 30 days (preferably
30 days for surgery) after valve implantation (i.e. baseline imaging),
at 1 year after implantation and annually thereafter [168]. The defin-
itions of structural valve deterioration and bioprosthetic valve failure
have recently been standardized in a consensus publication [168].
Indications for reintervention are detailed in the table of recommen-
dations for management of prosthetic dysfunction (section 11.2.3).
Percutaneous balloon interventions should be avoided in the
treatment of stenotic left-sided bioprostheses.
Transcatheter valve-in-valve implantation is now an option for
treating degenerated bioprostheses in patients with increased
surgical risk. Experience is mostly for bioprostheses in the aortic
position and remains limited in the mitral position and even
more so in the tricuspid position [205,206]. Valve-in-valve and
valve-in-ring procedures may be reasonable alternatives if the
patient is at increased surgical risk, but it is necessary that the
multidisciplinary Heart Team discusses every patient and chooses
the best individualized approach.
11.2.7 Heart failure. Heart failure after valve surgery should
lead to a search for prosthetic dysfunction or prosthesis-patient
mismatch, deterioration of repair, LV dysfunction or progression
of another valve disease. Non-valvular-related causes such as
CAD, hypertension or sustained arrhythmias should also be con-
sidered. The management of patients with heart failure should
follow the relevant guidelines [113].
Key points
• The choice between a mechanical prosthesis and a biopros-
thesis should not overstress the role of age and should take
into account the wishes of the informed patient.
Management of prosthetic valve dysfunction
Recommendations Classa Levelb
Mechanical prosthetic thrombosis
Urgent or emergency valve replacement is
recommended for obstructive thrombosis
in critically ill patients without serious
comorbidity.
I C
Fibrinolysis (using recombinant tissue plas-
minogen activator 10 mg bolus + 90 mg in
90 min with UFH or streptokinase
1 500 000 U in 60 min without UFH) should
be considered when surgery is not avail-
able or is very high risk or for thrombosis
of right-sided prostheses.
IIa C
Surgery should be considered for large
(>10 mm) non-obstructive prosthetic
thrombus complicated by embolism.
IIa C
Bioprosthetic thrombosis
Anticoagulation using a VKA and/or UFH is
recommended in bioprosthetic valve
thrombosis before considering
reintervention.
I C
Haemolysis and paravalvular leak
Reoperation is recommended if paravalvu-
lar leak is related to endocarditis or causes
haemolysis requiring repeated blood
transfusions or leading to severe
symptoms.
I C
Transcatheter closure may be considered
for paravalvular leaks with clinically signifi-
cant regurgitation in surgical high-risk
patients (Heart Team decision).
IIb C
Bioprosthetic failure
Reoperation is recommended in sympto-
matic patients with a significant increase in
transprosthetic gradient (after exclusion of
valve thrombosis) or severe regurgitation.
I C
Reoperation should be considered in
asymptomatic patients with significant
prosthetic dysfunction if reoperation is at
low risk.
IIa C
Transcatheter valve-in-valve implantation
in the aortic position should be considered
by the Heart Team depending on the risk
of reoperation and the type and size of
prosthesis.
IIa C
UFH: unfractionated heparin; VKA: vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
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• Patients with a mechanical prosthesis require lifelong treat-
ment using VKA with a target INR adapted to the prosthesis
and patient characteristics.
• Low-dose aspirin should be added to VKA only in selected
patients with a mechanical prosthesis who have atheroscler-
osis or recurrent embolism.
• The risk of thromboembolism and bleeding is higher during
the postoperative period and requires increased awareness of
the monitoring of anticoagulant therapy.
• The management of anticoagulant therapy during non-cardiac
surgery should be adapted to the type of surgery. Minor surgical
procedures generally do not require interruption of anticoagulation.
Figure 10: Management of left-sided non-obstructive mechanical prosthetic thrombosis. TE: thromboembolism; TOE: transoesophageal echocardiography; TTE:
transthoracic echocardiography.
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Gaps of evidence
• The safety and efficacy of very-low-target INRs (median <2.5)
in patients with a mechanical prosthesis in the aortic position
should be further studied.
• The safety and efficacy of NOACs in patients with a mechan-
ical prosthesis require further research.
• The safety and efficacy of low-dose aspirin associated with
contemporary target INRs in patients with a mechanical pros-
thesis, according to the presence or absence of atheroscler-
osis, require further evaluation.
• Optimal early antithrombotic therapy after implantation of
surgical and transcatheter aortic bioprostheses needs to be
better defined.
• Long-term outcome data of transcatheter valve-in-valve and
valve-in-ring procedures are required.
12. MANAGEMENT DURING NON-CARDIAC
SURGERY
Cardiovascular morbidity and mortality are increased in patients
with VHD who undergo non-cardiac surgery. Symptomatic se-
vere aortic stenosis or mitral stenosis may require valve replace-
ment or percutaneous intervention before non-cardiac surgery.
A detailed description of these recommendations is available
[196].
12.1 Preoperative evaluation
Echocardiography should be performed in any patient with VHD.
Determination of functional capacity is a pivotal step in pre-
operative risk assessment, measured either by exercise test or
ability to perform activities in daily life. The decision for manage-
ment should be taken after multidisciplinary discussion involving
cardiologists, surgeons and anaesthesiologists.
12.2 Specific valve lesions
12.2.1 Aortic stenosis. In patients with severe aortic stenosis,
urgent non-cardiac surgery should be performed under careful
haemodynamic monitoring.
The management related to elective non-cardiac surgery
depends on the presence of symptoms and the type of surgery
[196, 207, 208]. In symptomatic patients, aortic valve replace-
ment should be considered before non-cardiac surgery. In
patients at increased surgical risk, TAVI is a therapeutic
option. In asymptomatic patients, elective non-cardiac surgery
can be performed safely, albeit with a risk of worsening heart
failure [207, 208]. If non-cardiac surgery implies large volume
shifts, aortic valve replacement should be considered first
(Figure 11).
12.2.2 Mitral stenosis. Non-cardiac surgery can be performed
safely in patients with non-significant mitral stenosis (valve area
>1.5 cm2) and in asymptomatic patients with significant mitral
stenosis and a systolic pulmonary artery pressure <50 mmHg.
In symptomatic patients or in patients with systolic pulmonary
artery pressure >50 mmHg, correction of mitral stenosis, by
means of PMC whenever possible, should be attempted before
non-cardiac surgery if it is high risk.
12.2.3 Aortic and mitral regurgitation. Non-cardiac surgery
can be performed safely in asymptomatic patients with severe
mitral regurgitation or aortic regurgitation and preserved LV
function. The presence of symptoms or LV dysfunction should
lead to consideration of valvular surgery, but this is seldom
needed before non-cardiac surgery. If LV dysfunction is severe
(ejection fraction <30%), non-cardiac surgery should be per-
formed only if strictly necessary, after optimization of medical
therapy for heart failure.
12.3 Perioperative monitoring
Heart rate control (particularly in mitral stenosis) and careful fluid
management (particularly in aortic stenosis) are needed. TOE
monitoring may be considered.
Key points
• In symptomatic patients with severe aortic stenosis, aortic
valve replacement or TAVI should be considered before non-
cardiac surgery.
• In patients with severe mitral stenosis and symptoms or pul-
monary artery pressure >50 mmHg, PMC should be at-
tempted before non-cardiac surgery.
13. MANAGEMENT DURING PREGNANCY
Detailed guidelines on the management of cardiovascular disease
during pregnancy are available in another document [209].
The decision for management during pregnancy should be
taken after multidisciplinary discussion involving cardiologists,
obstetricians and anaesthesiologists [209]. Valve disease should
be evaluated before pregnancy and treated if necessary.
Pregnancy should be discouraged in severe mitral stenosis, severe
symptomatic aortic stenosis and with an aortic diameter >45 mm
in Marfan syndrome or > 27.5 mm/m2 in Turner syndrome.
Caesarean section is recommended for patients with severe
mitral or aortic stenosis, ascending aortic diameter >45 mm or
severe pulmonary hypertension, as well as women on oral anti-
coagulants in preterm labour.
13.1 Native valve disease
Moderate or severe mitral stenosis with a valve area <1.5 cm2 in
pregnant women is usually poorly tolerated. PMC should be con-
sidered in severely symptomatic patients (NYHA class III-IV) and/
or those with systolic pulmonary artery pressure >50 mmHg des-
pite optimal therapy. PMC should be performed after the 20th
week of pregnancy in experienced centres [209].
Complications of severe aortic stenosis occur mainly in pa-
tients who were symptomatic before pregnancy and among
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those with impaired LV function. Evaluation with an exercise test
is recommended before pregnancy.
Chronic mitral regurgitation and aortic regurgitation are well
tolerated, even when severe, provided LV systolic function is
preserved.
Surgery under cardiopulmonary bypass is associated with a
foetal mortality rate of 15–30% [210] and should be restricted to
the rare conditions that threaten the mother’s life.
13.2 Prosthetic valves
Maternal mortality is estimated at 1–4% and serious events occur
in up to 40% of women with mechanical valves [211].
Therapeutic anticoagulation is extremely important to avoid
complications. In patients requiring <_5 mg warfarin, oral anti-
coagulants throughout pregnancy and a change to UFH before
delivery is favoured. In patients requiring higher doses, switching
to LMWH during the first trimester with strict anti-Xa monitoring
(therapeutic range 0.8–1.2 IU/ml) and the use of oral anticoagu-
lants afterwards is favoured [209].
Key points
• Pregnancy should be discouraged in women with severe mi-
tral stenosis and severe symptomatic aortic stenosis.
• Pregnancy in women with a mechanical valve, especially
in the mitral position, is associated with a high risk for ma-
ternal and foetal complications. Therapeutic anticoagula-
tion during pregnancy is of utmost importance in these
patients.
Gaps in evidence
The optimal management of pregnant women with mechan-
ical heart valves with regards to the antithrombotic regimen
needs to be better defined.
Figure 11: Management of severe aortic stenosis and elective non-cardiac surgery according to patient characteristics and type of surgery. AS: aortic stenosis; AVR:
aortic valve replacement; BAV: balloon aortic valvuloplasty; TAVI: transcatheter aortic valve implantation.
aClassification into three groups according to the risk of cardiac complications (30-day death and myocardial infarction) for non-cardiac surgery (high-risk
>5%; intermediate risk 1–5%; low risk <1%) [196].
bNon-cardiac surgery performed only if strictly needed. The choice between percutaneous aortic valvuloplasty and TAVI should take into account patient
life expectancy.
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14. TO DO AND NOT TO DO MESSAGES FROM THE GUIDELINES
Recommendaons Classa Levelb
Management of CAD in paents with VHD (adapted from Windecker et al. [16])
Coronary angiography is recommended before valve surgery in paents with severe VHD and any of the 
following:
• history of cardiovascular disease
• suspected myocardial ischaemia
• LV systolic dysfuncon
• in men aged over 40 years and postmenopausal women
• one or more cardiovascular risk factors.
I C
Coronary angiography is recommended in the evaluaon of moderate to severe secondary mitral 
regurgitaon.
I C
CABG is recommended in paents with a primary indicaon for aorc/mitral valve surgery and coronary 
artery diameter stenosis ≥70%.
I C
Management of atrial ﬁbrillaon in paents with VHD
The use of NOACs is not recommended in paents with atrial ﬁbrillaon and moderate to severe mitral 
stenosis.
III C
NOACs are contraindicated in paents with a mechanical valve [45]. III B
A) Severe aorc regurgitaon
Indicaons for surgery
Surgery is indicated in symptomac paents [57,58,66,67]. I B
Surgery is indicated in asymptomac paents with resng LVEF ≤50% [57,58]. I B
Surgery is indicated in paents undergoing CABG or surgery of the ascending aorta, or of another valve. I C
Heart Team discussion is recommended in selected paents in whom aorc valve repair may be a feasible 
alternave to valve replacement.
I C
Aorc valve repair, using the reimplantaon or remodelling with aorc annuloplasty technique, is 
recommended in young paents with aorc root dilaon and tricuspid aorc valves, when performed by 
experienced surgeons. 
I C
Surgery is indicated in paents with Marfan syndrome, who have aorc root disease with a maximal 
ascending aorc diameter ≥50 mm. 
I C
Indicaons for intervenon in aorc stenosis and recommendaons for the choice of intervenon mode
B) Aorc root disease (irrespecve of the severity of aorc regurgitaon)
Intervenon is indicated in symptomac paents with severe, high-gradient aorc stenosis (mean gradient 
≥40 mmHg or peak velocity ≥4.0 m/s) [91-93].
I B
Intervenon is indicated in symptomac paents with severe low-ﬂow, low-gradient (<40 mmHg) aorc 
stenosis with reduced ejecon fracon, and evidence of ﬂow (contracle) reserve excluding pseudosevere 
aorc stenosis.
I C
Intervenon should not be performed in paents with severe comorbidies when the intervenon is unlikely 
to improve quality of life or survival.
III C
Aorc valve intervenons should only be performed in centres with both departments of cardiology and 
cardiac surgery on-site, and with structured collaboraon between the two, including a Heart Team (heart 
valve centres).
I C
The choice for intervenon must be based on careful individual evaluaon of technical suitability and 
weighing of risks and beneﬁts of each modality (aspects to be considered are listed in Table 7). In addition, 
the local expertise and outcomes data for the given intervention must be taken into account.
I C
SAVR is recommended in paents at low surgical risk (STS or EuroSCORE II <4% or logisc EuroSCORE I <10%
and no other risk factors not included in these scores, such as frailty, porcelain aorta, sequelae of 
chest radiation) [93].
I B
TAVI is recommended in paents who are not suitable for SAVR as assessed by the Heart Team [91,94]. I B
In paents who are at increased surgical risk (STS or EuroSCORE II ≥4% or logisc EuroSCORE I ≥10%, or other 
risk factors not included in these scores such as frailty, porcelain aorta, sequelae of chest radiation), 
the decision between SAVR and TAVI should be made by the Heart Team according to the individual 
patient characteristics (see Table 7), with TAVI being favoured in elderly patients suitable for 
transfemoral access [91,94-102]. 
I B
SAVR is indicated in asymptomac paents with severe aorc stenosis and systolic LV dysfuncon
 (LVEF <50%) not due to another cause.
I C
SAVR is indicated in asymptomac paents with severe aorc stenosis and abnormal exercise test showing 
symptoms on exercise clearly related to aorc stenosis.
I C
SAVR is indicated in paents with severe aorc stenosis undergoing CABG, or surgery of the ascending aorta 
or of another valve. 
I C
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Indicaons for intervenon in severe primary mitral regurgitaon 
Mitral valve repair should be the preferred technique when the results are expected to be durable. I C
Surgery is indicated in symptomac paents with LVEF >30% [121,131,132]. I B
Surgery is indicated in asymptomac paents with LV dysfuncon (LVESD ≥45 mm and/or LVEF 
≤60%) [122,131]. I B
Indicaons for mitral valve intervenon in chronic secondary mitral regurgitaon
Surgery is indicated in paents with severe secondary mitral regurgitaon undergoing CABG and LVEF >30%. I C
Indicaons for PMC and mitral valve surgery in clinically signiﬁcant (moderate or severe) mitral stenosis 
(valve area ≤1.5 cm²)
PMC is indicated in symptomac paents without unfavourable characteriscs for PMC [144,146,148]. I B
PMC is indicated in any symptomac paents with a contraindicaon or a high risk for surgery. I C
Mitral valve surgery is indicated in symptomac paents who are not suitable for PMC. I C
Indicaons for tricuspid valve surgery 
Surgery is indicated in symptomac paents with severe tricuspid stenosis. I C
Surgery is indicated in paents with severe tricuspid stenosis undergoing le-sided valve intervenon. I C
Surgery is indicated in paents with severe primary tricuspid regurgitaon undergoing le-sided valve surgery. I C
Surgery is indicated in symptomac paents with severe isolated primary tricuspid regurgitaon without 
severe right-ventricular dysfuncon.
I C
Surgery is indicated in paents with severe secondary tricuspid regurgitaon undergoing le-sided valve 
surgery.
I C
Choice of the aorc/mitral prosthesis – in favour of a mechanical prosthesis; the decision is based on the 
integraon of several of the following factors
A mechanical prosthesis is recommended according to the desire of the informed paent and if there are no 
contraindicaons to long-term ancoagulaon.
I C
A mechanical prosthesis is recommended in paents at risk of accelerated structural valve deterioraon. I C
Choice of the aorc/mitral prosthesis – in favour of a bioprosthesis; the decision is based on the integraon 
of several of the following factors
A bioprosthesis is recommended according to the desire of the informed paent. I C
A bioprosthesis is recommended when good-quality ancoagulaon is unlikely (compliance problems, not 
readily available) or contraindicated because of high bleeding risk (previous major bleed, comorbidies, 
unwillingness, compliance problems, lifestyle, occupaon).
I C
A bioprosthesis is recommended for reoperaon for mechanical valve thrombosis despite good long-term 
ancoagulant control.
I C
Indicaons for anthromboc therapy in paents with mechanical prostheses and bioprostheses
Oral ancoagulaon using a VKA is recommended lifelong for all paents [179,180]. I B
Mechanical prostheses
Bridging using therapeuc doses of UFH or LMWH is recommended when VKA treatment should be 
interrupted.
I C
INR self-management is recommended provided appropriate training and quality control are performed [181]. I B
The use of NOACs is contraindicated [45]. III B
Oral ancoagulaon is recommended lifelong for paents with surgical or transcatheter implanted 
bioprostheses who have other indicaons for ancoagulaon.
I C
Management of prosthec valve dysfuncon 
Bioprostheses
Urgent or emergency valve replacement is recommended for obstrucve thrombosis in crically ill paents 
without serious comorbidity.
I C
Ancoagulaon using a VKA and/or UFH is recommended in bioprosthec valve thrombosis before 
considering reintervenon.
I C
Reoperaon is recommended if paravalvular leak is related to endocardis or causes haemolysis requiring 
repeated blood transfusions or leading to severe symptoms.
I C
Reoperaon is recommended in symptomac paents with a signiﬁcant increase in transprosthec gradient 
(aer exclusion of valve thrombosis) or severe regurgitaon.
I C
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15. WHAT IS NEW IN THE 2017 VALVULAR HEART DISEASE GUIDELINES?
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(France), Ioan Mircea Coman (Romania), Veronica Dean
(France), Victoria Delgado (The Netherlands), Donna Fitzsimons
(UK), Oliver Gaemperli (Switzerland), Gerhard Hindricks
(Germany), Bernard Iung (France), Peter Ju¨ni (Canada), Hugo A.
Katus (Germany), Juhani Knuuti (Finland), Patrizio Lancellotti
(Belgium), Christophe Leclercq (France), Theresa McDonagh
(UK), Massimo Francesco Piepoli (Italy), Piotr Ponikowski
(Poland), Dimitrios J. Richter (Greece), Marco Roffi (Switzerland),
Evgeny Shlyakhto (Russia), Iain A. Simpson (UK), Jose Luis
Zamorano (Spain).
ESC National Cardiac Societies actively involved in the re-
view process of the 2017 ESC/EACTS Guidelines for the man-
agement of valvular heart disease:
Armenia: Armenian Cardiologists Association, Hovhannes K.
Kzhdryan; Austria: Austrian Society of Cardiology, Julia
Mascherbauer; Azerbaijan: Azerbaijan Society of Cardiology,
Fuad Samadov; Belarus: Belorussian Scientific Society of
Cardiologists, Vadim Shumavets; Belgium: Belgian Society of
Cardiology, Guy Van Camp; Bosnia and Herzegovina:
Association of Cardiologists of Bosnia and Herzegovina, Daniela
Loncar; Croatia: Croatian Cardiac Society, Daniel Lovric;
Cyprus: Cyprus Society of Cardiology, Georgios M. Georgiou;
Czech Republic: Czech Society of Cardiology, Katerina
Linhartova; Denmark: Danish Society of Cardiology, Nikolaj
Ihlemann; Egypt: Egyptian Society of Cardiology, Magdy
Abdelhamid; Estonia: Estonian Society of Cardiology, Teele
Pern; Finland: Finnish Cardiac Society, Anu Turpeinen; Former
Yugoslav Republic of Macedonia: Macedonian FYR Society of
Cardiology, Elizabeta Srbinovska-Kostovska; France: French
Society of Cardiology, Ariel Cohen; Georgia: Georgian Society
of Cardiology, Zviad Bakhutashvili; Germany: German Cardiac
Society, Hu¨seyin Ince; Greece: Hellenic Society of Cardiology,
Manolis Vavuranakis; Hungary: Hungarian Society of
Cardiology, Andras Temesvari; Iceland: Icelandic Society of
Cardiology, Thorarinn Gudnason; Ireland: Irish Cardiac Society,
Darren Mylotte; Israel: Israel Heart Society, Rafael Kuperstein;
Italy: Italian Federation of Cardiology, Ciro Indolfi; Kazakhstan:
Association of Cardiologists of Kazakhstan, Yury Pya; Kosovo:
Kosovo Society of Cardiology, Gani Bajraktari; Kyrgyzstan:
Kyrgyz Society of Cardiology, Alina Kerimkulova; Latvia: Latvian
Society of Cardiology, Ainars Rudzitis; Lithuania: Lithuanian
Society of Cardiology, Vaida Mizariene; Luxembourg:
Luxembourg Society of Cardiology, Fre´de´ric Lebrun; Malta:
Maltese Cardiac Society, Daniela Cassar Demarco; Morocco:
Moroccan Society of Cardiology, Latifa Oukerraj; The
Netherlands: Netherlands Society of Cardiology, Berto J.
Heart Team
658 ESC/EACTS Guidelines / European Journal of Cardio-Thoracic Surgery
Downloaded from https://academic.oup.com/ejcts/article-abstract/52/4/616/4095090
by University of Zurich user
on 03 April 2018
Bouma; Norway: Norwegian Society of Cardiology, Terje
Kristian Steigen; Poland: Polish Cardiac Society, Monika Komar;
Portugal: Portuguese Society of Cardiology, Luisa Maria De
Moura Branco; Romania: Romanian Society of Cardiology,
Bogdan A. Popescu; Russian Federation: Russian Society of
Cardiology, Vladimir Uspenskiy; San Marino: San Marino
Society of Cardiology, Marina Foscoli; Serbia: Cardiology
Society of Serbia, Ljiljana Jovovic; Slovakia: Slovak Society of
Cardiology, Iveta Simkova; Slovenia: Slovenian Society of
Cardiology, Matjaz Bunc; Spain: Spanish Society of Cardiology,
Jose´ Antonio Vazquez de Prada; Sweden: Swedish Society of
Cardiology, Martin Stagmo; Switzerland: Swiss Society of
Cardiology, Beat Andreas Kaufmann; Tunisia: Tunisian Society
of Cardiology and Cardio-Vascular Surgery, Abdallah
Mahdhaoui; Turkey: Turkish Society of Cardiology, Engin
Bozkurt; Ukraine: Ukrainian Association of Cardiology, Elena
Nesukay; United Kingdom: British Cardiovascular Society,
Stephen J. D. Brecker.
We wish to thank Professor A. Pieter Kappetein for his advice
and contribution to these guidelines.
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